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Summary 
Summary 
 
Hepatocyte growth factor (HGF), its receptor c-Met and Interleukin-6 (IL-
6) together with its signalling transducer gp130 are important mediators of liver 
regeneration and mediate hepatoprotective effects. C-Met and HGF are 
essential for liver development during embryogenesis and it was shown that 
HGF/c-Met mediated signalling is essential for the regeneration of the liver after 
an injury. IL-6/gp130 mediated signalling is important for the regulation of the 
acute phase response after an acute liver injury, the modulation of liver 
regeneration and immune cell homeostasis. 
The aim of this thesis is to define the effects of HGF/c-Met and IL-
6/gp130 dependent signalling in the model of bile duct ligation (BDL) that 
induces a chronic cholestatic liver injury, which leads to liver fibrosis. In this 
thesis, wildtype-mice (c-Met/gp130loxP/loxP), conditional c-Met knockout mice (c-
MetΔhepa), conditional gp130-deficient mice (gp130Δhepa) and conditional c-
Met/gp130-double-deficient mice (c-Met/gp130Δhepa) were subjected to BDL for 
up to 4 weeks.  
 The conditional knockout-mice where generated by using the cre-loxP-
system under the control of a hepatocyte-specific albumin-promoter. The first 
efforts to generate hepatocyte specific c-Met knockouts with a pre-natal 
activated albumin promoter resulted in embryonic lethality. The change to a 
post-natal, hepatocyte-specific albumin promoter allowed the generation of 
viable offspring carrying a hepatocyte specific c-Met deficiency. 
It was shown that depletion of c-Met results in a higher grade of liver 
injury, which is ascribed to a greater sensitivity to FAS-induced apoptosis by 
lack of c-Met mediated anti-apoptotic gene-expression. In concordance with the 
liver injury, c-Met-deficient mice displayed a stronger liver inflammation 
compared to c-Met/gp130loxP/loxp-mice. This together with the lack in anti-
apoptotic gene expression finally results in a higher degree of liver fibrosis. 
A further part of this thesis investigates the contribution of HGF/c-Met 
and IL-6/gp130 to the regulation of the acute phase response. After BDL gp130 
and c-Met/gp130Δhepa displayed a high mortality rate during the first 7d after 
BDL, in contrast to this, c-MetΔhepa and wildtype-mice survived without a case of 
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death. The reason for enhanced mortality was linked to a bacterial induced 
sepsis, and comparative signalling pathway analysis and gene expression 
studies revealed a lack of acute phase response and antibacterial signalling in 
gp130Δhepa and c-Met/gp130Δhepa mice strains. In contrast to this, c-MetΔhepa-
mice had a reduced, but still present acute phase response. 
Both, c-Met and gp130, do contribute to liver protection and play an 
important role for the regulation and modulation of the acute phase response as 
well. They participate in specific signalling pathways like anti-apoptotic 
signalling in the case of c-Met and anti-bacterial signalling in the case of gp130 
in pathway and ligand specific manner. 
These findings lead to a further and more detailed understanding of the 
signalling specific effects mediated by c-Met and gp130 during chronic 
cholestatic liver disease. Those findings can support the eforts to find a cure 
against fibrosis and helps to improve the treatment of bacterial induced sepsis.  
 II
1. Introduction 
1. Introduction 
1.1. Receptor Tyrosine Kinases 
A functional receptor tyrosine kinase (RTK) contains an extracellular ligand 
binding domain, a transmembrane domain and a cytosolic kinase domain. This 
basic structure is rarely found in nature and in most cases high structural 
differences occur between the different RTKs (1). This allows different RTK-
families to be defined. Common identified structures are IgG-domains, 
Fibronectin-type-3-domains and Cystein-rich domains, which are found in 
numerous RTKs (1). RTKs mediate their signals by phosphorylation. In most of 
the cases, the aminoacid tyrosine is phosphorylated and transmitting the signal 
to target proteins (2). The molecular  phosphate is derived from the clevage of 
ATP (3). The avtivation is due to the binding of a specific ligand (4) followed by 
receptor dimerization (5) and later autophosphorylation (6). Receptor tyrosine 
kinases form homodimers or heterodimers to activate specific signalling 
pathways (5, 7). Most RTKs are found present as monomers in the membrane, 
the exception being the insulin receptor family, which do form dimers after 
ligand interaction (7). The intracellular signalling mediated by RTKs is essential 
for the development and the maintenance of homeostasis of multicellular 
organisms (3). 
 
1.2.1. Structure of c-Met and HGF 
Met (mesenchymal-epithelial transition factor) is a RTK that was first 
identified in the early 1980s because of its role in oncogenesis (8, 9). The first 
isolated isoform of the c-Met receptor was discovered as a mutation called 
TPR-Met (translocated promoter region fused to met) whereas the 
protooncogen was discovered later (10). 
The receptor tyrosine kinase c-Met is a 1368 aminoacid (AA) protein, which is 
organized in a short α- and a long β-chain. The α-chain and the first 212 AA-
residues of the β-chain are essential for the receptor ligand interaction. The β-
chain contains the ectocellular domain, as well as the transmembrane domain 
and the intracellular kinase domain. 
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To activate c-Met specific signalling, the HGF-receptor forms a dimeric 
protein, linked by a disulfide bridge at the aminoacids (AA) 307 and 308. (11). 
C-Met induced signal transduction is a complex mechanism which is highly 
regulated by 1.) adaptor proteins and 2.) the ability to activate the JAK-STAT-
pathway. The activation of both pathways depends on phosphorylation of 
specific signalling transduction mediators (12). 
The ligand of the receptor tyrosine kinase c-Met is hepatocyte growth 
factor (HGF). HGF belongs to the group of polypeptide growth factors (12). This 
heterogeneous group regulates the growth, movement and differentiation of 
higher eukaryotic cells.  
Sequential analysis allowed the identification of 8 different families of 
growth factors (shown in table 1). Growth factor activity is mediated via specific 
membrane receptors that transduce the growth factor signal into the cell (12). 
HGF was simultaneously identified as a growth factor for hepatocytes 
and as a fibroblast derived effector of epithelial movement and interaction (13-
15). HGF is a 728 AA protein, which is processed from an inactive precursor by 
proteolytic cleavage.  
 
Familiy Members 
Insulin/IGF IGF1-6, 
EGF/TGF-α EGF, TGF-α, Neuregulin 1-4 
PDGF PDGFA-D, VEGF 
NGF Neutrophins 
FGF FGF1-10 
TGF-β TGF-β1, GDF9, Myostatin, BMPs 
Hematopoetic growth factors EPO, TPO 
Plasminogen related growth factors HGF, HGFL/MSP 
Table 1: Presented here are the 8 different families of growth factors with chosen 
examples for their members 
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Figure 1: Structure of the c-Met receptor tyrosine kinase: Shown here are the crystal 
structure and the schematic organisation of the HGF receptor c-Met. The extracellular domain 
contains the α-chain with the Sema-domain (Sα) which is important for the rector ligand 
interaction. The β-chain also starts with a smaller Sema-domain(Sβ), followed by a cystein-rich 
domain(C). The 4 Ig-domains (Ig1-Ig4) are subsequently connected to the intracellular Kinase-
domain (K) (taken from Birchmeier, C, “Met Metastasis, Mortality and more”, Nature Cell 
Biology Reviews, 2004) 
 
HGf has been shown to be evolutionary conserved with data demonstrating its 
existence up to 500 million years ago (16). This finding suggests a fundamental 
role of HGF and its receptor c-Met in evolution. Hitherto 2 proteases, urokinase 
(17) and tissue plasminogen activator (18) were described to be capable of 
cleaving the biologically inactive pro-HGF isoform into the mature, biologically 
active isoform. HGF forms a heterodimer containing a larger α (64KDa) and a 
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smaller β subunit (34KDa) (19). The receptor ligand interaction involves the N-
terminal domain of HGF (20).  
 
 
Figure 2: HGF processing from its inactive precoursor HGF is synthesised as an inactive 
precursor. It is processed between argenine 494 (R) and valine 495 (V). The stability of the 
processed and activated HGF molecule is linked via a disulfide bridge between the α- and the 
β-chain. (Taken from Matusmo K., “HGF: Renotropic role and potential therapeutics for 
renal diseases”, Kidney International, 2001) 
 
HGF is a potent mitogen for its target cells. Furthermore, it has been shown that 
HGF is involved in regenerative processes, cell cycle progression and cell 
development as well as recruitment of progenitor cells (21) and the maturation 
of macrophages (22). 
 
1.2.2 c-Met mediated Signal transduction 
HGF/c-Met mediated signaltransduction is transmitted via Grb2 
associated binding protein 1 (Gab1). Gab1 belongs to an evolutionary old family 
of signal mediators. Structural analysis of Gab1 revealed a unique 13 AA long 
specific region, which is called c-Met binding-site. This site enables Gab1 to 
bind to tyrosines (Y) 1349 & 1356, which are phosphorylated following receptor 
ligand interaction. Furthermore, this site is also used by other adaptor proteins 
such as growth factor receptor bound protein 2 (Grb2) (12).  
It has been described that Gab1 binds to Y1349 and that Grb2 binds to 
Y1356. In the following, both molecules interact and form dimeric or multimeric 
complexes (23). Gab1 has been found to be essential for directing c-Met 
dependent signalling to relay proteins SHP2, PI3K, phospholipase C and CRK. 
All of these relay-proteins contain a Src-homology domain-2 (SH2), which 
usually binds to phosphorylated tyrosine residues (24). Activation of these 
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proteins results in the further activation of downstream components of the 
ERK/MAPK-pathways such as Ras and Raf (25). C-Met alone is able to 
mediate signalling, but it has also been shown that c-Met forms heterodimers 
with other cellular surface receptors to mediate distinct signalling events. 
Currently, interactions have been described to occur with CD44 (26), β4-integrin 
(27), Ezrin (28), Fas-receptor (29), Semaphorin-receptor (30) and E-cadherin. 
 
 
Figure 3: Effects induced by HGF/c-Met mediated signaltransduction HGF induces the 
autophosphorylation of intracellular c-Met and initiates the activation of adaptor proteins. This 
activates several distinct pathways, which are involved in survival, proliferation and 
development of a cell. (Taken from Matusmo K., “HGF: Renotropic role and potential 
therapeutics for renal diseases”, Kidney International, 2001) 
 
The cooperation between Met and the other receptors has not been linked 
directly to genetic relevance. However, these interactions may contribute to the 
stabilisation of c-Met signalling (12).  
Prior investigations were able to demonstrate the importance of c-Met 
mediated during embryonic development in vertebrates (12). C-Met and HGF 
form a unique ligand receptor interaction. Furthermore, it is known that co-
receptors like CD44 (31) and β-integrin (32) do not participate in signal 
mediation without other receptors. The signal transduction is dependent on 
phosphorylation of Gab1. C-Met knockouts and Gab1 knockout mice displayed 
a similar phenotype in embryonic development (23). The earlier discussed 
signal transmission via Gbr2 seems to be irrelevant for development (33). 
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In Danio rerio, also known as zebrafish, a common model for organ and 
tissue development, c-Met was identified as a differentiation factor. It was 
shown that endodermal as well as mesodermal genes like Sox17 and the hgf1 
mRNA expression were detectable (34).  
In mouse embryos it has been described that HGF/c-Met mediate 
essential signals for proliferation and for the survival of hepatocytes and 
placental trophoblasts (21, 35). The deletion of c-Met in the liver during early 
stages of embryonic development results in embryonic lethality (21, 35, 36). A 
further characteristic of c-Met deletion in the liver, in mice as well as in zebrafish, 
was the reduced size of the liver (21, 34). 
Another cell species which was found to be affected by HGF/c-Met 
signalling are neurons. C-Met depleted mice revealed a strong reduction of 
sensoric as well as sympatic and motor neurons (37).  
It has also been shown that c-Met affects angiogenesis. HGF/c-Met was able to 
form branched tubules, which led to the concept that c-Met is not only involved 
in the generation of the entire blood vessel network, but also contributes to its 
regeneration (15, 38).  
Further findings demonstrate that c-Met is involved in the migration of 
progenitor cells, which are important to form various tissues and organs during 
embryonic development (12). Studies of embryonic development have shown 
that the deletion of HGF/c-Met results in missing limb muscles. These are 
known to be derived from progenitor cells (39). The exact function of HGF/c-Met 
in this process can be defined as the ability to release the progenitor cells from 
their source and allowing them to travel (40). This delamination capacity was 
only provided by c-Met and the fibroblast growth factor-receptor 1 (12). HGF/c-
Met are not only involved in the release of progenitor cells but also seem to 
function as a cytokine to guide the progenitor cells to their final destination (40). 
This can be demonstrated by finding high expression levels of HGF-mRNA in 
the mesenchyma, where these cells are released, and  continues to be 
expressed along the route to their final target throughout development (40).  
All these findings demonstrate the high influence and the fundamental exigency 
of c-Met in vertebrate embryonic development.  
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1.2.3 c-Met signalling in liver disease 
The most common disease in which c-Met and its ligand HGF have been 
shown to be involved are tumors. In general, overexpression of either HGF or c-
Met can led to the generation of tumorigenic or metastatic cells. Different 
tumors and metastatic lesions have been observed, in mouse models, when 
either HGF or c-Met were overexpressed. Furthermore, analysis of human 
tumors revealed that c-Met and HGF were frequently expressed in tumors and 
metasis. To date detection of over- and/or misexpression of c-Met and HGF 
have been correlated with a poor survival prognosis in cancer patients. C-Met 
derived tumors are not limited to the liver, but have also been detected in lung, 
skin and colon (12).  
Several studies have described c-Met and HGF as protective factors in 
the case of metabolic liver injury. In alcoholic steatohepatitis (ASH), HGF was 
found to be produced by Kupffer-cells and c-Met was only produced by 
hepatocytes (41). Apolipoprotein-b (Apo-B) and very low density lipoprotein 
(VDL) were discovered as direct targets upregulated by c-Met (42), whereas 
sterol regulatory element binding protein-1 (SREBP-1) and Steroyl-CoA 
desaturase have been shown to be downregulated following activation of 
HGF/c-Met signalling pathways (42). The inhibition of c-Met signalling pathways 
in fatty liver diseases results in a higher rate of apoptosis mediated via 
transglutaminase 2 (Tg2), which silences the c-Met regulated transcription 
factor SP1 and induces the activation of the proapoptotic Fas-receptor pathway 
(43). In the case of Fas-R induced apoptosis the identification of the YGLA-
domain and the treatment of fatty liver diseases in dietary mouse models with 
recombinant YGLA domain resulted in reduced apoptosis of hepatocytes and 
reduced expression of profibrotic genes such as collagen 1α1 (43). Further 
experiments in the BDL model showed that the administration of HGF via an 
expression plasmid led to the resolution of liver fibrosis (44). To compensate for 
liver damage, hepatocytes re-enter the cell cycle and undergo mitosis to replace 
liver mass. HGF/c-Met has been shown to be the crucial factor in this process. 
Absence of this signalling pathway results in a delayed S-phase entry and in 
concordance with this in a missing Erk1/2 activation and a delayed AKT 
activation (45). 
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Those findings underline the high protective impact of HGF/c-Met mediated 
signalling during liver disease, but they also show the risk associated with the 
use of HGF and c-Met as a therapeutic target. 
 
1.2.4 c-Met as a therapeutic target 
Presently, there are two approaches to target c-Met therapeutically. One 
is the expression of HGF to activate curative signalling of c-Met. It has been 
shown that HGF/c-Met signalling is beneficial for restoring the liver in a model of 
chronic cholestatic liver damage and dimethylnitrosamine induced liver fibrosis 
(44), (46). It has been demonstrated that HGF can mobilize progenitor cells to 
migrate to heart and kidney to re-establish organ homeostasis following injury 
(47). Furthermore, in the case of colon injury, HGF led to an increase of cell 
proliferation and finally reconstitution of healthy colon epithelial (48). The 
beneficial effect of HGF to neurons after spinal cord injury is a very interesting 
aspect. Beside the effects of angiogenesis and prolonged cell survival also 
axonal regrowth was observed (49). These data indicate that HGF and c-Met 
have a great therapeutic potential after disruption of organ homeostasis 
following an injury. However, the approach of HGF-distribution as a cure is quite 
risky, due to the observation in several cancers of disequilibrium of ligand and 
receptor expression. 
A second approach to use c-Met as a therapeutic target is the inhibition 
of c-Met signalling by use of c-Met inhibitors. This treatment has mainly been 
used for the inhibition of cancer growth or metastasis. The targets for the 
inhibition of c-Met and the mediated events by its activation are shown in Figure 
3.  
One approach utilized to inhibit c-Met signalling was to snatch HGF from 
its receptor by using a soluble c-Met-isoform (decoy c-Met), consisting of only 
the extracellular domain of the HGF-R (50), or by using a recombinant Sema 
domain-isoform (Sema). This domain is required for the binding of HGF and the 
dimerization of c-Met. The usage of this Sema-domain as an inhibitor might also 
lead to the interference with other RTK, due to the presence of the Sema 
domain in semaphorin receptors. However, together with anti-c-Met antibodies, 
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the recombinant Sema-domain seems to be a powerful tool to downregulate c-
Met activation in cancer cells (51).  
 
 
Figure 4: Therapeutical targets in the HGF/c-Met pathway: 1) Catching HGF by binding to 
soluble c-Met or the Sema domain, 2) Inhibitory antibodies against c-Met, 3) HGF-antagonist 
HGF-NK4, 4) HGF neutralizing antibodies, 5) Inhibition of the activation of the RTK-domain, 6) 
Inhibition of the docking site for SHP2, 7) RNA-inteference for c-Met or HGF, 8) Prevention of 
protein processing, 9) Pathway inhibition (taken from Met decoys: Will cancer take the bait? 
Zhang YW, Cancer Cell 2004) 
 
The ligand HGF was be a target for therapeutic antibodies as well (52). 
This approach also prevents an interaction between the ligand and its receptor 
and thereby preventing the activation of c-Met signalling. A further approach to 
disable the activation of c-Met was the usage of a HGF antagonist, known as 
HGF/NK4. Its structure is highly similar to HGF, but inhibits the invasive growth 
of tumors and induces apoptosis in tumor cells (53). C-Met signalling can also 
be affected in an intracellular manner by preventing the interaction between the 
effector protein Grb2 and c-Met via the SH2-domain (54) or by using dominant 
negative c-Met molecules (55). Because ATP is essential for the activation of 
the RTK a small molecule, with ATP-binding site competitive features did 
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reduce the kinase activity of c-Met and inhibits tumor growth as well ((56). A 
further approach was the usage of ribozymes to perform RNA-inference for 
HGF or c-Met mRNA. In this approach, adenoviral expressed ribozymes 
digested the mRNA of either HGF or c-Met post transcription and inhibited 
angiogenesis and promoted apoptosis (57). Beside the possibility of inhibiting 
the translation by mRNA degradation, it was also possible to interfere on the 
level of protein folding. Use of Geldanamycin, an antibiotic, resulted in 
chaperone inactivation and led to degradation of the c-Met pre-protein (58). So 
far, a lot of strategies for inhibiting c-Met mediated signalling are available. 
Whether they will ever enter the clinical routine remains unclear. 
 
1.3. The IL-6 cytokine family and its signal transducer 
gp130 
 
1.3.1 The IL-6 Family 
The IL-6 cytokine family is defined as a group of about 10 cytokines of a 
size between 180-200 AA. The analysis of their crystal structure revealed that 
they all do share a 4 α-Helix bundle. The sequence homology between these 
cytokines is ~20% (59). To date, gp130 homologs have only been identified in 
mammals, but hitherto no gp130 cytokinehomologs were identified in other 
vertebrates as for example pisces or amphibian. Although an interesting 
discovery was made by Rollman et al. in 1999. They were able to isolate a sex 
pheromone protein from salamanders that revealed sequence similarities to 
gp130 cytokines (60).  
A common feature of the IL-6 cytokine family is that they share the same 
signalling transducer, namely glycoprotein 130 (gp130 also known as CD130). 
Gp130 is a glycolated and, in most of the cases, a membrane resident protein. 
It can be anatomically structured into 3 modules, the Fibronectin III-like domain 
(FNIII), Ig-like domain (IgD) and the cytokine receptor homology domain (CHD). 
The receptors for this group of cytokines are shared by several ligands.  
Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary neurothrophic 
factor (CNTF) and Cardiotrohin-1 (CT-1) for example use heterodimers of the 
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LIF-receptor (LIFR) and gp130 as a co-receptor for signal transduction (61), 
(62), (63), (64). 
 
 
Cytokine Size (in AA) Molecular Mass (KDa) 
IL-6 184 21-28 
IL-11 178 23 
LIF 180 45 
CNTF 200 21-28 
CT-1 201 21,5 
OSM 196 28 
IL-31 163 18,1 
Table 2: Current members of the IL-6 family with size and molecular mass 
 
A little variation of this model is made by OSM and CNTF which form a 3 
receptor ligand interaction complex with their receptors as subunits of the entire 
signalling complex.  
 
 
Figure 5: Combustion of the IL-6 cytokines and their receptors 
This figure displays the signalling complexes of the IL6-family cytokines (taken from 
Interleukin-6 Cytokine signalling through the JAK-STAT-pathway, Heinrich P.C., The 
Biochemical Journal 1998) 
 
Homodimers of gp130 are utilised by the Interleukins (IL) 6 and 11. Both 
cytokines bind to their own primary receptor and form a complex with 2 gp130 
molecules (65), (66). The recently discovered IL-31 is OSM-R dependent and 
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forms a heterodimer with its own, gp130-like receptor IL-31R. IL-31 is the only 
IL-6 family member whose signalling is completely gp130 independent (67).  
The biological effects mediated by IL-6 cytokines are pleiotrophic and 
contribute to proliferation, development, immune modulation and regeneration 
(68). It has been demonstrated that prenatal deletion of gp130 in mice resulted 
in embryonic lethality similar to what has been described for c-Met (69). 
Postnatal deletion of gp130, employing the cre/loxP system to delete gp130 in a 
tissue specific manner, results in demylenation of peripheral nerves, 
thrompocytopenia and an impairment of the acute phase response (70). 
 
1.3.2. IL-6 signalling 
The binding of one IL-6 family member to its cognate receptor results in 
the recruitment of the co-receptors like LIF-R OSM-R and in most of the cases 
gp130. In the case of IL-6 two ways of signalling are known, a classical pathway 
and a transsignalling pathway. The classical pathway is initiated by the binding 
of IL-6 to its membrane bound receptor IL-6R (CD126/IL-6Rα).The binding of 
IL-6 leads to the recruitment of gp130, which activates in the following the JAK-
STAT-pathway via phosphorylation of the signal mediation kinases. The 
classical pathway is mostly activated in hepatocytes, neutrophils, 
macrophages/monocytes and some lymphoctes subspecies (71), (72), (73) 
during the early immune response and regulates the expression of acute phase 
proteins like Serum Amyloid A2 (SAA2) or C-reactive protein (CRP). The acute 
phase response is the imidiate response to inflammation, physical trauma or 
malignancy and is strictly regulated by the IL-6/gp130-JAK-STAT3-axis. In vivo-
studies in IL-6 knockout and transgenic mice illustrated that IL-6 is the main 
mediator of the acute phase response (APR) after inflammation (74). The acute 
phase response is characterized by fever, upregulated cytokine expression and 
infiltration of immune cells. The liver itself contributes to the acute phase 
response by producing acute phase proteins like SAA (75) and cytokines such 
as  IL-6, IL-8 and TNF-α. 
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Figure 6: Classical and Trans signalling of IL-6 Shown here are the current models for 
classical and trans-signalling of IL-6. Panel A describes the classical signalling pathway with 
membrane bound IL-6R, whereas Panel B shows the Trans-signalling pathway with the soluble 
IL-6 receptor (taken from Impact of Interleukin-6 classic and trans-signalling on liver 
damage and regeneration, Drucker, C.  Journal of Autoimmunity, 2009) 
 
Furthermore, it regulates the homeostasis of the APR and absence of the IL-
6/gp130 signalling leads to a loss of the acute phase response (75), (76), (77). 
A second pathway, which is activated by gp130 after complex formation with IL-
6, for example, is the Ras pathway. It has been shown for embryonic stem cells, 
that activation of STAT3 is important for the stem cell renewal, whereas the 
activation of the Ras/Raf/Erk pathway is associated with cellular differentiation 
and proliferation. The activation of the gp130 signalling via PI3K leads to the 
inactivation of pro-apoptotic pathways and contributes to cell survival (see (78) 
for review). 
The alternative pathway of IL-6 induced signaltransduction is the 
transsignalling pathway (72, 73). In this case, IL-6 binds to a soluble isoform of 
its receptor, which interacts to the membrane attached gp130 and then induces 
the known and previously described signalling pathway. In addition to the 
soluble IL-6R, a soluble gp130 isoform has been described. This isoform acts in 
competition with the membrane bound gp130 and has an inhibitory function 
towards IL-6 signalling (79). The formation of the soluble isoforms of IL-6R is 
due to two mechanisms. The first is the proteolytic cleavage of membrane 
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bound IL-6R by the metalloproteases ADAM10 and 17 (80) or by alternative 
splicing, which excises the membrane-spanning domains, thereby generating a 
soluble IL-6R isoform (81). Interestingly, the soluble IL-6R only activates gp130 
via the transsignalling and results in an increased IL-6 sensitivity in cells such 
as embryonic stem cells, hematopoietic progenitor cells, T-cells, mesothelial 
cells, smooth muscle cells, neural cells and endothelial cells.  
The IL-6/gp130/STAT pathway is regulated by the suppressor of cytokine 
signalling (SOCS) gene family. In particular, SOCS3 is involved in the feedback-
regulation of the IL-6-gp130-JAK-STAT3-signalling pathway (82) by inhibiting 
the acitivity of the Janus Kinase (JAK) (83, 84). This inhibition was shown to be 
a common feature of all SOCS proteins. Differences have been reported for 
binding sites that do vary from one SOCS protein to another. SOCS1 for 
example was shown to bind to the activation loop of JAK, whereas SOCS3 
inhibits JAK-activation by binding to the SH2 domain (83, 84). 
 
1.2.4 IL-6 and gp130 in liver disease and liver regeneration 
In the liver, IL-6 and gp130 are involved in already described functions, 
such as regeneration, proliferation, modulation of the early immune response 
and regulation of the acute phase response (74). Depletion of gp130 in the liver 
results in an abrogation of the APR and a higher degree of liver injury (74, 76, 
77). The IL-6-gp130-JAK1-STAT3 pathway has been identified as playing a 
critical role in liver protection. Multiple mouse models have been used to study 
the effects of bacterially induced sepsis (77), apoptosis and fibrosis (85, 86), 
autoimmune hepatitis (87) and liver regeneration (88, 89) and demonstrate the 
importance of the IL-6 mediated pathways for liver protection and its 
regeneration.  
Intensive investigations identified the acute phase protein Serum Amyloid 
A as one of the most important targets of the IL-6/gp130 pathway in the liver (77, 
90). Lack of IL-6 can be compensated by other factors of the IL-6 family (90), 
whereas the lack of gp130 leads to lethal phenotypes in the various liver injury 
models (75-77, 87, 90). A deeper analysis of T-cell mediated hepatitis in mice 
unravelled the CXC-cytokine KC as an IL-6/gp130 regulated molecule with liver 
protective potential (87) in addition to the known molecule SAA2. 
 14
1. Introduction 
It was shown by Kovalovich et al. that IL-6/gp130 as well as HGF/c-Met 
acts contrary to Fas-induced apoptosis by inducing and stabilizing the 
expression of antiapoptotic factors as Bcl2 and Bcl-xL (86). In the chemotoxic 
CCl4 model of liver injury in mice, it was exerted that gp130 activates NFkB as 
well as STAT3, both of which act in a liver protective manner (85). It was also 
shown that gp130 signalling is not only protective for hepatocytes, but that non-
parenchymal and immune cells also depend on a functional gp130 signalling 
pathway to protect against liver fibrosis (76).  
Investigations of liver regeneration by employing the partial hepatectomy 
model revealed that gp130 deficiency causes a blunted activation of NFkB and 
AP-1 mediated gene transcription (75). IL-6/gp130 mediated signalling 
contributes to the homeostasis of apoptosis and compensatory proliferation 
after partial hepatectomy (75). Furthermore, it has been demonstrated by 
Dierssen et al. that the gp130 mediated activation of STAT3 controls the G0/G1 
cell cycle transition of hepatocytes via SOCS3 and additionally provides 
protective signals during stress conditions (89). IL-6 plays a crucial role in 
regulating the acute phase response by activating target genes such as SAA. 
By using the Lipopolysaccharide (LPS)-model in mice it can be shown that in 
sepsis induced liver damage IL-6/gp130 contributes to liver protection by 
activation of the STAT3 signalling pathway. Furthermore, it contributes to the 
control of the inflammation by regulating the activation and translocation of 
NFkB to the nucleus (77). The findings regarding NFkB are conflicting with the 
observations descriped by Kovalovich et al. 
In addition to its role in the liver, IL-6 and its transducer gp130 are 
involved in inflammatory mediated diseases, such as inflammatory bowel 
disease and artherosclerosis. Currently, there are investigations and clinical 
trials where two designer proteins, hyper-IL-6 and sgp130Fc, are tested. Hyper-
IL-6 is a fusion protein of the human IL-6R and human IL-6, linked together by a 
peptide bridge, which mimics the activated transsignalling. 
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Figure 7: Structure of Hyper-IL-6 and sgp130Fc Hyper-IL-6 (A) and sgp130Fc (B) are both 
designed fusion proteins, which are functional active in vivo and currently under investigation in 
clinical trials. (taken from Impact of Interleukin-6 classic and trans-signalling on liver 
damage and regeneration, Drucker, C.  Journal of Autoimmunity, 2009) 
 
It is 102 to 103 times more potent to induce IL-6 signalling than 
endogenous IL-6 pathways (91). The sgp130Fc is composed of the extracellular 
domain of gp130, which is linked to the Fc-portion of a human IgG antibody. 
The function of sgp130Fc is to inhibit the transsignalling pathway of IL-6 by 
preventing the IL-6/sIL-6R complex to bind to membrane bound gp130 (see (92) 
for review). A further approach is the usage of neutralizing antibodies against 
IL-6 (93), thereby effectively inhibiting the classical IL-6 signalling pathway. 
However, the binding of IL-6 to the antibody leads to an increase of IL-6 levels, 
which negatively impacts disease progression (94). 
The contribution of IL-6 to liver disease has been extensively studied in 
mice, and it has been demonstrated that in a model of acute liver failure (D-
Galactosamine) administration of Hyper-IL-6 lead to an improved survival. This 
was due to a stronger induction of cell proliferation and reduced apoptosis in the 
liver (95). Also in the partial hepatectomy model, additional treatment with 
Hyper-IL-6 led to a faster and better regeneration of the liver, displayed by 
reduced levels of transaminases and a prolonged STAT3 activation (95-97). 
Investigations with Concavalin-A (ConA), a mouse model which mimics an 
autoimmune disease, have also shown that pre-treatment with IL-6 resulted in 
reduced liver damage, whereas treatment after Con-A distribution resulted in an 
 16
1. Introduction 
enhanced liver damage (98). The effect of IL-6 in the hepatotoxicity model CCl4 
was already described above. In the last couple of years it turned out more and 
more that IL-6-gp130 is a wolf in a sheep’s clothing in regarding to 
carcinogenesis. Similar to c-Met and HGF, IL-6 also possesses a pro-oncogenic 
potential. Recent studies with male mice have shown that IL-6 induced cancer 
after treatment with the carcinogenic molecule diethylnitrosamie (DEN), 
whereas female mice were protected because of their estrogen production. The 
carcinogenic pathway can furthermore be linked to the Toll-like receptor (TLR) 
adaptor protein MyD88. Analysis in MyD88 knockout mice demonstrated that no 
hepatocellular carcinoma (HCC) occurred following DEN-treatment (99).  
Not only is the absence of gp130-mediated signalling harmful for the liver, 
but the lack of the counter regulatory parts such as SOCS3 also results in 
enhanced liver fibrosis (100). In addition, the absence of SOCS3 has also been 
found in some types of HCC (100), which implies that hyperactivation of STAT3 
by IL6-gp130 has been demonstrated to be a critical factor for development of 
carcinogenesis (104). It was shown that single nucleotide polymorphisms in the 
gene-locus of gp130 have been linked to HCC development in human as well 
(101). The procarcinogenic potential of IL-6-STAT3 signalling was recently 
described in the development of colorectal cancer (102). The same group 
furthered this study by describing a beneficial effect though inhibiting the IL-6 
pathway, highlighting a potential treatment against colorectal cancer (102). Due 
to the availability of several antagonistic antibodies and JAK inhibitors, several 
of which are currently being tested in clinical trials, this seems to be a promising 
approach to treat cancer with these drugs (103). 
 
 1.3 Liver fibrosis 
The development of fibrosis or scarring is the wound healing response 
following liver injury. This process is characterized by the accumulation of 
extracellular matrix (ECM) (104, 105), leading to a disruption of the liver 
architecture. Chronic or prolonged liver fibrosis eventually proceeds to liver 
cirrhosis. This change is characterised by hepatocellular dysfunction, resistance 
to hepatic blood flow, which leads to hepatic insufficiency, and portal 
hypertension (105). The injury stimulus does not have to be a chronic feature, 
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because an acute liver injury is able to activate mechanisms involved in fibrosis 
progression. The liver injury origin stimulus might be cause from viral origin 
(HCV/HBV) (106), but can also come from metabolic syndromes (Non-
Alcoholic-Steato-Hepatitis/NASH) (107, 108) and drug abuse (Alcohol-Steato-
Hepatitis/ASH) (105). A turning point in the research of liver fibrosis was the 
discovery of hepatic stellate cells (HSCs) as the main source of collagen 
production in liver fibrosis by Scott Friedman and his colleagues (109). A key 
event inHSC activation is the loss of vitamin A storage abilities and the 
production of α-smooth muscle actin (α-SMA).  
 
 
Figure 8: Induction and progression of liver fibrosis Shown in figure 8 is the induction and 
the progression of fibrosis after a liver injury together with the effects that lead to either 
resolution of fibrosis or to chronic injury, which leads to severe liver fibrosis 
 
One of the strongest factors involved in stellate cell activation and 
priming of liver fibrosis is transforming growth factor-beta1 (TGF-β1) (110, 111). 
This growth factor is derived from autocrine and paracine sources and activates 
the SMAD signalling pathways. In particular, SMAD 2 and 3 are activated via 
phosphorylation in HSCs. SMAD activation is also involved in priming stellate 
cells for fibrotic development (112-114). The characteristic collagen expression 
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is stimulated by TGF-β1 via a C/EBP-β dependent mechanism. The profibrotic 
effect of TGF-β1 is not only restricted to hepatic stellate cells (115), the 
hepatocyte itself is also sensitised by TGF-β1. This leads to an upregulation of 
connetive tissue growth factor (CTGF) and the hepatocyte propagates the 
stellate cell activation by autocrine mechanisms (116-118). Other recently 
discovered activation factors are the apoptotic bodies, which result from the 
death of parenchymal liver cells, and the DNA from these apoptotic hepatocytes 
activates stellate cells by interaction with TLR9 (119). 
Another aspect of stellate cell activation is the reentry into cell cycle, 
which is mediated by PDGF-isoforms and other mitogens such as VEGF, 
Thrombin, EGF, TGF-α and FGF, etc (105).  
However, stellate cells do not only function as inductors of liver fibrosis. 
Recently published data illustrated that activated stellate cells do also express 
the stem cell receptor CD133 (120). These data have lead to the speculation 
that they may function via transdifferentiation as real liver progenitor cells. 
Responsible for this potential are the Wnt and the Hegdehog signalling 
pathways (121, 122). Further evidence for this role of hepatic stellate cells in the 
niche is proposed (123). These findings did also enrich the discussion that, for 
example, the hepatocellular carcinoma following a HCV-infection induced liver 
fibrosis can also be stem cell derived (124). A result of stellate cell activation is 
the enrichment of ECM and the main sources of collagen production are the 
HSCs derived myofibroblasts (125). It is also found that the depletion of MMP-
13 in mouse liver leads to a reduced liver fibrosis in the bile duct ligation model 
(126). Another liver resident cell species, in addition to stellate cells and 
hepatocytes, are Kupffer-cells. These are described as liver resident 
macrophages, which are also important mediators of liver injury and a main 
source of the pro-apoptotic tumor necrosis factor-alpha (TNF-α). Kupffer-cells 
are also sensitive to oxidative stress and do contribute to stellate cell activation 
(127, 128). After the injury stimulus and the subsequent activation of HSCs, 
they do migrate, guided by chemokines such as MCP-1 (129), CXCR3 ligands 
(130) or also PDGF, which not only functions as a proliferation mediator but 
also as a chemokine (131, 132). 
The approaches of an antifibrotic therapy are various. The most favored 
is the inhibition of stellate cell activation, which can be achieved by using 
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antioxidants like vitamin E, Silymarin, phosphatidylcholine etc, which inhibit 
stellate cell activation, the key event in the induction of liver fibrosis (133-136).  
Another molecule that does inhibit the stellate cell activation is Interferon-
γ. It was discovered to have inhibitory effects on stellate cell activation in animal 
model. (137). Also, the use of synthetic ligands was tested for peroxisome 
proliferators activated nuclear receptors (PPAR). All of these receptors are 
present on the surface of stellate cells and especially a synthetic PPAR-γ 
seems to inhibit stellate cell activation (42, 138).  
Another approach in antifibrotic therapy is usage of growth factors. The 
delivery by gene therapy attenuated liver fibrosis, but this is still on an 
experimental status and further analysis is still pending. The risk of using growth 
factors is that their overexpression during therapy may lead to cancer 
development (139, 140).  
A further approach is the reduction of liver inflammation (141). Since 
TNF-α is one fo the major pro-inflammatory cytokines such as antibodies and 
soluble TNF-receptor were used and already tested in mouse models of 
hepatitis (142, 143).  
Beside inhibition of stellate cell activation another option is to neutralize 
the proliferative response of stellate cells. The theory of this treatment was to 
inhibit the cytokine mediated effects on stellate cell proliferation (144).  
But not only inhibition of proliferation seems to be promising. For this, two 
factors have to be eliminated, first the profibrotic TGF-β1 cytokine and second 
the stability of collagen mRNA (145, 146). But up to now, experiments with 
TGF-β1 antagonists, inhibiting antibodies and soluble receptors are just on 
preliminary stages.  
In addition to inhibition of the proliferation response the inhibition of 
matrix generation was also aimed as a therapeutical target. A direct antagonist 
of collagen expression, Halufoginone, has been tested so far in several models 
of tissue fibrosis (147, 148). More experiences have been made with the direct 
administration of MMP-mRNA by gene therapy. The results of animal models 
confirm that in principle matrix can be resorbed (149, 150). The usage of 
mesenchymal stem cells might also be a possible approach to regenerate an 
established liver fibrosis (151, 152). It finally remains that liver fibrosis can 
potentially be targeted by several strategies. Time will tell which strategy - drug 
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treatment, antagonist usage or gene therapy or a combination of approaches - 
will be the method of choice for the cure of liver fibrosis. 
 
1.4 The Acute Phase Response 
The acute phase response (APR) is characterized as an early and 
immediate set of reactions in response to an injury, trauma or infection of a 
tissue (153). The induction of the APR is regulated, in most cases without 
regard of the initiating event, by monocytes or macrophages (153). The earliest 
cytokines that are released for the initiation of the APR-cascade are IL-1, TNF-α 
and IL-6 (153). The liver plays a central role during the APR. It is not only 
producing the acute phase plasma proteins (APPs), it is also involved in the 
detoxification of harmful agents and the initiation of regeneration (77, 154). The 
mediators of APP expression were found to be cytokines of the IL-6 family (IL-6, 
IL-11, LIF, OSM, CTNF), the IL-1-family (IL1α & β) and TNF-α-superfamily 
(TNF-α & β). Growth factors (HGF, IGF, insulin, FGF, TGF-β) and 
Glucocorticoids (Cortisol) modulate the effects induced by cytokines (154). It 
was shown in mouse models that IL-6/gp130 mediated STAT3 activation was 
essential for a normal progression of the APR and for a beneficial outcome (74, 
77). Besides STAT3 activation (77, 155), NFκB (Nuclear Factor kappa B) and 
C/EBP-β (CCAAT/enhancer binding protein beta) were also shown to be 
involved in the expression of acute phase plasma proteins (156-158).  
Turning off the inflammatory response is a critical event in the resolution 
of the APR. First, the initiating cytokines cascade by IL-1, TNF-α and IL-6 has to 
be inhibited or turned off. Second, antiinflammatory cytokines like IL-4 and IL-10 
do have to initiate the countersignalling in the organ, e.g. the liver. It was 
demonstrated that IL-4 expression is associated with a reduced accumulation of 
monocytes in tissue (159, 160). The cytokine IL-10 is produced by Th2-
lymphocytes and inhibits cytokine synthesis in macrophages and monocytes 
(161, 162). Together with the stimulation of corticosteroids by the adrenal-
pituitary, IL-4 and IL-10 seem to be the essential components to terminate the 
APR correctly (153).  
Taking a more detailed look at the impact of the liver during the acute 
phase response, it was demonstrated that deficiency in IL-6 or gp130 results in 
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stronger liver damage and a lack of the APR (74, 76, 77). Specifically SAA 
mRNA, one of the main APPs, is no longer induced and the liver damage is 
increased in various liver injury models. Furthermore, the expression of 
proinflammatory cytokines was increased and a higher number of immune cells 
were recruited to the liver (75-77, 87, 163). Additionally, it was demonstrated 
that gp130 mediated signal transduction and STAT3 driven gene expression 
during the APR was essential for survival during bacterial induced sepsis (163). 
 
1.5 The Bile duct ligation model 
The bile duct ligation (BDL) model is an experimental model to induce 
cholestasis and liver injury in rats or mice, which nicely correlates with 
cholestatic liver injury in humans (164). Cholestasis can also occur as a 
consequence of genetic defects in human,. known as Byler´s disease (defect on 
Chromosome 18q21-22) (165) or Dubin-Johnson syndrome (166, 167). 
To induce cholestasis, the common bile duct is ligated (163, 168, 169). 
Cholestasis is defined as an impairment to secret bile compounds (bile salts 
and various organic anions) into the bile duct and loss of the osmotic driving 
force for bile secretion (170). In addition to the BDL as an experimental model 
of cholestasis, the use of endotoxines (LPS) and the resulting production of 
cytokines can also cause a sepsis induced cholestasis. Furthermore, 
cholestasis is also induced by drugs such as cyclosporine A and 
chlorpromazine in humans and animals. The BDL model is used not only to 
study cholestasis but also to investigate processes related to fibrogenesis (171, 
172), infection (173)) and hepatic ischaemia (168). 
Hallmarks of effects induced by BDL are inflammation (168, 169), biliary 
and parenchymal proliferation (168) as well as  the induction of large areas of 
necrosis (169). Neutrophils have been identified as the major group of 
infiltrating immune cells into the liver following BDL (174, 175). Furthermore, 
detectable parameters during a cholestatic liver injury are elevated serum levels 
of bilirubin (169) and transaminases (168). Together with the BDL also 
enhanced numbers of bacteria were described to occur 7 days after BDL (163). 
The turnover from acute to chronic cholestatic damage is made around day 7 
post BDL (168). After 28 days high numbers of large and small bile duct 
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proliferates are detectable in the liver. Also, an elevated expression of 
profibrotic genes such as collagen1α1 and its inhibitor TIMP-1 was detected in 
the liver (168). In summary, the BDL model represents a powerful tool to 
investigate cholestasis induced sepsis as well as liver fibrogenesis. 
 
1.6 Aims of this study 
HGF/c-Met and IL-6/gp130 are both involved in the regulation of acute 
and chronic liver injury. However, little is known about their co-operative 
regulation of hepatocellular homeostasis. Therefore a model of cholestatic liver 
injury was established to investigate c-Met and gp130 dependent signalling 
pathways in hepatocytes. Another aspect was to investigate the contribution of 
HGF/c-Met and IL-6/gp130 signalling events to the acute phase response after 
cholestatic liver injury. In this study the molecular targets of c-Met mediated 
signalling during APR-induction will be investigated in detail.  
Furthermore, we aimed to unravel how other mediators of antibacterial 
signalling and acute phase modulation might be canonically regulated by 
HGF/c-Met and IL-6/gp130. 
A more detailed analysis of these pathways might lead to the 
identification of new therapeutic targets that was be beneficial for the treatment 
of acute liver injury and liver fibrosis. This ultimately might reduce the number of 
fibrotic patients that develop liver cirrhosis and eventually neoplastic liver 
lesions. It might also help to find new cures against bacterial induced sepsis 
during cholestatic conditions. 
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2. Material and Methods 
 
2.1 Methods 
2.1.1 Bile duct ligation 
 
8-10 week old mice were narcotised using 0,01% Xylazinhydrochloride/ 
1% Ketaminhydrochloride mixture, diluted in 0,9% NaCl. Per each 10g body 
weight of the mouse, 100µl of the narcotisation-solution was administrated. 
After reflex control and affirmation of narcotisation, the abdominal wall 
was sterilized by using Antifect®. Afterwards the peritoneum was opened by a 
diagonal, 1,2-1,5 cm long cut. Then the bile duct was ligated 4mm before its 
entry into the pancreas. Thereafter the peritoneum was closed using a 
continuous fissure. The upper fur was closed using single knots. Subsequent 
after the operation mice received 150µg Temgesic® i.p. to avoid pain induced 
stress.  
 
2.1.2 Serum preparation 
 
Blood samples were taken by eye bleeding. Therefore the mice were 
narcotized by using Isoflorane. After verification of narcotized condition the 
plexus retro-orbitalis was punted by using a glass capillary. The blood was 
captured in an Eppendorf tube. Approximately 200-500µl, depending on time of 
experiment, were taken. After chilling for 15 minutes at room temperature, the 
serum was separated by spinning at 10000 rpm for 10 minutes in a tabletop 
centrifuge and stored for further analysis at -20°C. 
 
2.1.3 DNA-isolation from mouse tails 
 
The isolation of genomic DNA from tail biopsies was performed with a 
Proteinase K-digestion step in Tail-lysis-buffer (see Buffer section). For this the 
tails were incubated for 2h up to an overnight incubation at 56°C on a shaker 
running at 1400 rpm. 
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After the digestion of the tail DNA was isolated using isopropanol precipitation 
at room temperature. after spin down of the precipitate the occurring DNA-pellet 
was washed twice with 70% ethanol to remove isopropanol leftovers, which 
might interfere with the PCR reaction. The entire ethanol was removed and the 
pellet was dried for 15 min at 35°C. After the pellet is dehumidified well, it was 
resuspended in 500µl dH20. To enhance dissolving of the DNA pellet, the tube 
was shaken at 1400 rpm for 15-30 minutes. 
 
2.1.3 Generation of hepatocyte specific knockout mice 
 
To achieve a hepatocyte specific deletion of c-Met the Cre-loxP-system 
was used. In this system the Cre-recombinase gets activated by a specific gene 
product. The Cre-recombinase recognizes the loxP-sides, which are flanking 
the genomic sequence that is supposed be deleted. After excision the genomic 
DNA is realigned by the Cre-recombinase.  
The expression of the Cre-recombinase was under the control of albumin 
promoter/enhancer structures. The first approach to generate a hepatocyte 
specific c-Met deficient mouse was by using an embryonal stage expressed 
Cre-recombinase (Alfp-cre), which was activated at day 10.5 (77). The floxed c-
Met mice were kindly provided by Prof. Carmen Birchmeier from Max 
Delbrueck-Center in Berlin (45).  The second approach was an after birth 
activated cre-recombinase (AlbP-cre), which was activated 2 weeks after birth.  
 
Figure 9: Floxed exons of the c-Met and the gp130 gene  Displayed are the schematic 
drawings of loxP flanked exons. Exon 15 is encoding the ATP binding side of c-Met (according 
to Borowiak, PNAS 2004). In the case of gp130, the deleted exon 15 is encoding for the 
transmembrane region. The gp130 loxP-sides are a corrected version of Betz, J Exp Med 1998 
(personal communication with Sara D. Suckett, PhD and Prof. Dr. C Trautwein) 
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The postnatal activated promoter/enhancer construct was also kindly 
provided by the lab of Prof. Carmen Birchmeier from the Max Delbück-Center. 
Those mice carrying loxp-sides for the exon 15 of c-Met were crossed with the 
prenatal expressed Alfp-cre and with the postnatal activated AlpP-cre mice. 
Prenatal activation resulted in embryonic lethality (see Results, Figure 10), 
whereas the approach with the postnatal activated Cre-recombinase was able 
to generate viable offspring. For the generation of c-Met/gp130Δhepa depleted 
mice, cre-postive c-Met knockout mice were crossed together with cre-negative 
homozygous flanked gp130 mice. The heterozygous offspring was then bred 
among each other to generate the c-Met/gp130 double deficient mice or gp130 
single deficient mice.  
The animals were bred under standardized conditions following National 
Academy of Sciences (NIH publication 86-23 revised 1985) criteria in the animal 
research institute “Institut für Tierversuchskunde” of the University Hospital 
Aachen (UK Aachen). The animals were kept under a 12h light-dark rhythm, 
standardized temperature 20-24°C and humidity 50-60% was maintained by 
central air conditioning. Mice were kept in macrolon cages providing food and 
water ad libitum. After seperating the litter mates from the breeding couples, tail 
tip biopsies were taken after ear marking and DNA was isolated for genotyping. 
All studies were approved accoring to German legal requirements 
(Tierversuchsantrag 50.204.2-AC5a, 37/05). 
 
2.1.4 Genotyping PCR for Alb-cre, c-Met, gp130 
 
To determine the genotype of the mouse, PCR-reaction was performed. 
The reaction itself was made as followed and used for all the following PCR-
protocols. 
Reagent Vol [µl] 
2x Red Taq Master Mix 10µl 
Primer fwd 0,8 µl 
Primer rev 0,8 µl 
dH2O 6,4 
cDNA 2µl 
Total 20µl 
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For detection of the loxP-sides the following PCR-protocols were performed. 
 AlbP-cre     
 Step Temp [°C] Time 
Denaturation 95 3 min  
 Denaturation 95 30 sec 
Annealing 62 30 sec 
Elongation 72 30 sec 
Hold 4 ∞ 
 
 
 
 
 
c-Met 
 Step Temp [°C] Time 
Denaturation 95 3min 
Denaturation 95 30 sec 
 
 
 
Annealing 62 30 sec 
Elongation 72 30 sec 
Hold 4 ∞ 
 
 
 
 
 gp130 
 
Step Temp [°C] Time 
Denaturation 95 3 min 
 
 
Denaturation 95 30 sec 
Annealing 54 30 sec 
Elongation 72 1 min 
Hold 4 ∞ 
32x 
30x 
32x 
 
 
 
 
 
 
2.1.5 Immunostaining for BrDU 
For the detection of proliferating hepatocytes mice were injected 2h 
before sacrifice with 900µg BrdU. BrdU stains specifically those cells, which are 
in the DNA-synthesis phase (S-phase) of the cell cycle. 
Cryopreserved liver tissue was cut in 5 µm thickness by using a cryotome. 
Sections were fixed by incubation in ice cold acetone for 20 minutes and 
afterwards rehydrated in PBS. The sections were acidified by incubation with 
2N HCL for 30 minutes. The HCL was neutralized by 0,1 M sodiumborate for 9 
minutes. The sodiumborate was removed by repetitive washing in H2O. Next, 
the slides were washed 3x10 minutes in PBS. Detection of BrDU was 
performed with a mouse-anti-BrDU antibody in a 1:40 dilution in PBS/1%BSA 
over night at 4°C. After primary antibody incubation, the washing step with PBS 
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was repeated three times. To detect the primary antibody a secondary anti-
mouse IgG antibody labelled with ALEXA488 flourescent dye was diluted 1:200 
in PBS/1%BSA and incubated for 1h at room temperature. The antibody was 
removed by washing with PBS 3x10 minutes. After counterstaining of the nuclei 
with DAPI enriched mounting medium, slides were observed for BrDU-positive 
nuclei. Positive nuclei per view field were counted and set into percentage 
relationship to DAPI-nuclei. All of the histological analysis was performed on an 
AxioImager Z1 from Zeiss. 
 
2.1.6 Immunostaining for CD4+-cells 
Cryopreserved sections were fixed in 95% ethanol at room temperature. 
Superfluous fixative was removed by 3x repeated washing step for 10 minutes. 
To block unspecific binding sites, the sections were treated with 20% goat 
serum in PBS. Afterwards, the primary anti-CD4 antibody, directly labelled with 
ALEXA488® fluorescent dye, was incubated overnight at 4°C in a 1:100 dilution 
in PBS/1,5% goat serum. After overnight incubation, the redundant antibody 
was washed away with PBS and the sections were counterstained with DAPI, 
distributed in the mounting medium. Per each view field, the total amount of 
CD4+-cells were counted and compared directly in between the used genotypes.  
 
2.1.7 Immunostaining for F4/80+ cells 
Crysections were fixed in 4% PFA for 20 minutes. Fixative was washed 
by 3x washing with PBS, containing sodium acid. The blocking of unspecific 
antigens was made with 0,2% BSA in PBS/acid for 5 minutes at RT. A primary 
rat-anti-mouse antibody against the F4/80-antigen was incubated for 1h at RT in 
PBS/1% mouse serum in a 1:100 dilution. Remaining antibody was removed by 
washing with PBS/sodium acid 3 times. After the washing, a second blocking 
step was performed as described before. The detection was made with a 1:200 
diluted anti-rat Cy3 labelled antibody, incubated for 1h at RT in PBS/sodium 
acid containing 1% mouse serum. Following this incubation step, the washing 
procedure was repeated three times. Counterstaining for nuclei was performed 
by DAPI containing mounting medium. F4/80+ cells were counted per 7-10 view 
fields. 
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2.1.8 Immunostaining for CD11b+ cells 
Staining procedure as described for F4/80+-cells. 
 
2.1.9 Immunostaining for Ly6G+ cells 
Staining procedure as described for F4/80+-cells above. 
 
2.1.10 Proof of the depletion of the c-Met on mRNA level 
To proof that the depletion in cre-positive mice is really effective, reverse-
transcription PCR was performed. The primers were designed to anneal in the 
exons 14 and 16 on mRNA-level to proof the deletion of exon 15. If the exon 15 
is still present in the mRNA, a 349 basepairs (bp) long PCR product should be 
detected, whereas in the case of excision, a 279 bp PCR-fragment should be 
observed. The primersequence is shown in table “2.3.10 Genotyping primers 
Met-KO cDNA”.  
The preparation of RNA for later cDNA generation was performed 
according to the general protocol described under “2.1.12 RNA-extraction from 
total liver”. cDNA transcription was performed according to the manufacturer 
using the Omniscript cDNA Kit® from Qiagen. To avoid unspecific PCR products, 
a Hot-Start Taq-polymerase® from Qiagen was used. After performing of the 
PCR run, the reaction was supplemented with 5µl DNA-loading buffer. 
 
Reagent Vol [µl] 
Hot Start Taq 12,5 
Primer fwd [10µM] 1 
Primer rev [10µM] 1 
dH20 8,5 
cDNA 2µl 
Total 25 
 
 
 
 
 
 
 29
2. Material and Methods 
The PCR reaction protocol was performed as followed. 
 
Step Temp [°C] Time 
Denaturation 95 15 min 
Denaturation 94 30 sec. 
Annealing 53 30 sec. 
Elongation 72 30 sec. 
Hold 4 ∞ 
 
 
 
30x  
 
 
 
 
20µl of the total PCR reaction was loaded on a 2% agarose gel and run 
at 180V for 30 minutes to achieve a proper separation of the PCR products. The 
DNA was labelled by ethidiumbromide used in a 1x10-6 dilution. The PCR 
products were detected on the BioDoc Analyze® UV-transilluminator from 
Biometra.  
 
2.1.11 RNA-extraction from total liver 
Isolation of RNA is a first step to analyse gene expression patterns in a 
cell or organ. RNA was isolated by using the guanidinium thiocyanate/phenol 
method.  
First, a small piece of liver was cut from frozen tissue. This piece was 
transferred into a tube containing 1mL of pegGold RNA-Pure-solution®. The 
tissue was homogenized with an Ultra-Thurax®. In the following, the 
homogenate was rested at room temperature for 5 minutes. After this, 200µl 
cholorform was added and mixed thoroughly by vortexing for 30 second. The 
mixture was chilled on ice for up to 10 min. To separate the cell wreckage and 
the proteins from the RNA, the tube with the homogenate was centrifuged for 5 
minutes at 12000 rpm at 4°C. After this step a clear separation of nucleid acids 
and proteins was visible. The upper, aquatious phase was transferred into a 
new Eppendorf tube and touching of the intermediate was avoided. To 
precipitate the nucleic acids, 500µl isopropanol was added to the aquatious 
phase and vortexed again for up to 30 seconds. The reaction was chilled at 
room temperature for up to 15 minutes and later centrifuged by 12000 rpm for 
10 minutes at 4°C. The RNA was precipitated and appeared as a white pellet at 
the bottom of the tube. The supernatant was decanted and leftovers of it were 
removed by pipetting carefully and avoiding pellet contact. The pellet was 
 30
2. Material and Methods 
washed twice by using RNase free, 70% ethanol. Each washing step included a 
centrifugation step at 12000rpm for 10 minutes at 4°C. After washing and 
removal of ethanol the pellet was air-dried for 5 minutes until it became slightly 
see-through.  It was solved in 70µl RNase free H2O at 56°C for 15-20 minutes. 
 
2.1.12 Gene expression analysis via Real-Time PCR 
To analyse the expression of a specific gene, it is possible to perform a 
so called Real-Time PCR. For this step it is necessary to transcribe RNA into 
cDNA as described under “2.1.10 Proof of the depletion of the c-Met on mRNA-
level”. The total transcribed cDNA was filled up to a final volume of 150µl.  
For the Real-Time PCR analysis a master mix containing primer, dH20 
and a 2x Sybr-Green mastermix (dNTPs, Reactionbuffer, hot start DNA 
polymerase) were mixed according to the following table. 
 
Reagent Vol [µl] 
Sybr GreenER™ 2x Mastermix 12,5 
Primer fwd [10µM] 0,6 
Primer rev [10µM] 0,6 
dH20 6,3 
Total 20 
 
20µl of this mastermix was pipetted in each well. After this, 5µl of cDNA 
template was added into each well.  
The program variations were dependent on the annealing temperature of 
the used primers. The quantification was a relative quantification against a 
housekeeping gene like GAPDH or 18s rRNA is suitable for this. 
 
General Real-Time PCR-protocol: 
 
 
 
 
 
 
 
Step Time [minutes] Temp [°C] 
Inititiation 2:00 50 
Activation 10:00 95 
Denturation 0:15 95 
Annealing & Amplification 1:00 58-60 
Denaturation 0:15 95 
Annealing 0:30 60 
Denaturation 0:15 95 
40x
Melting curve 
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The data were collected by the SDS analysis software provided by the 
manufacturer. Analysis of data sets was performed with the analysis feature of 
the SDS-software. The induction of gene expression was calculated according 
to Pfaffl method. 
 
2.1.13 Western-Blotting 
Signal transduction analysis was performed by Western-Blot. To 
separate the proteins according to their molecular weight, they were run on a 
Sodium dodecyl sulphate polyacrylamid gel electrophoresis (SDS-PAGE) 
according to Laemmli (176). The gel run was at 25mA/gel for one hour. The gel 
was wet blotted for 90 minutes on a nitrocellulose membrane.  
 
Antibody Dilution Incubationbuffer
pSTAT3 1:1000 5%BSA 
pSTAT1 1:1000 5% BSA 
STAT1 1:1000 5%BSA 
pc-Met (pY1230;1234&1235) 1:750 5% Milkpowder 
pJNK 1:1000 5% BSA 
JNK 1:1000 5% BSA 
SOCS3 1:1000 5% BSA 
α-Tubulin 1:1000 5% Milkpowder 
GAPDH 1:5000 5% Mlikpowder 
Secondary anti-mouse antibody (HRP-labelled) 1:2000 5% Milkpowder 
Secondary anti-rabbit antibody (HRP-labelled) 1:2500 5% Milkpowder 
 
To control the consistent blotting of the proteins, the membrane was 
stained with Ponceau red solution. To avoid unspecific binding of the antibody, 
the membrane was blocked for 1h according to the protocol of the manufacturer: 
TBS-T with 5%BSA or 5% milkpowder. After blocking, the first antibody 
incubation was followed according to the instructions of the provider, in general 
over night at 4°C in blocking solution or 5% BSA. After the primary antibody 
incubation, the membrane was washed in TBS-T three times for 10 minutes. 
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The incubation with a secondary horseradish peroxidase labelled antibody was 
performed for 1h in TBS-T. To remove unbind antibody, the membrane was 
washed 3 times for 5 minutes in TBS-T. To detect the proteinbands, the 
membrane was incubated for 1 minute in ECL (enzymatic chemiluminescences) 
solution. This solution was removed and the membrane embedded between two 
clear foils. The detection itself was performed with x-ray films.  
2.1.14 Terminal deoxynucleotidyl transferase dNTP nick and       
    labelling (TUNEL) 
Cryopreserved liver samples were cut 5 µm thick and fixed in 4% 
paraformaldehyd. After the fixation, the sections were washed in PBS 3 times 
10 minutes. To have access to the DNA, the nuclei were permeabelized in 0,1% 
Trition-X 100 and 0,1 % Na-Citrate in PBS for 2 minutes. The permeabilization 
solution was removed by washing 3x times for 10 minutes in PBS. The labeling 
solution was composed as seen in the table at the end of this section. 
 
Reagent Volume [µl] 
Enzyme solution 1 
10x TUNEL Diluent Buffer 9 
TUNEL labelling Solution 90µl 
Total 100µl 
 
30µl of labelling reaction was spread on each section and incubated over 
night at 4°C. After labelling of the DNA strandbreaks, the sections were washed 
and mounted with DAPI for nuclear counterstaining. The percentage of TUNEL 
positive cells was counted and set in percentage relationship to TUNEL 
negative, DAPI positive cells. 
 
2.1.15 Germ assay from liver 
To determine whether there are different bacterial loads in the liver of the 
different genotypes, liver samples were taken from mice, who were subjected to 
BDL for 3 days. In the following, total livers were isolated and homogenized by 
using a syringe pistil and pottered through a cell strainer with a mesh size of 
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70µm. The cell-strainer was washed twice with 500µl of autoclaved and sterile-
filtered LB medium.  
The homogenate was diluted 1x10-2 and 1x10-3 in antibiotics free, sterile 
filtrated LB medium. 50µl of each dilution was spread on an antibiotics free LB-
plate. The plates were incubated overnight at 37°C.  
 
2.1.16 Germ-Assay from blood 
To analyse the bacterial load in the blood of bile duct ligated mice, blood 
was taken retro-orbitally by using autoclaved capillaries and after desinfection of 
the area surrounding the eye to avoid contamination of surfacial germs. The 
blood was diluted 1x10-2 and 1x10-3 in antibiotics free, sterile filtrated LB 
medium and spread on an LB agar plate without antibiotics.  The plates were 
incubated overnight at 37°C. 
2.1.17 Lysogeny broth (LB) -media and agar plates 
The medium is composed with NaCl, yeast extract and tryptone. The 
ingredients were mixed in Millipore H2O and autoclaved. For agar plates, 10g 
agar-agar was added to 1L medium before autoclaving. Afterwards, it was 
poured on Petri dishes under sterile conditions.  
 
2.1.18 Protein extraction from total liver 
Protein analysis was made from whole liver extracts. Rice grain sized 
pieces of liver were homogenized on ice in protein extraction buffer (according 
to “2.3.6 whole cell protein extraction buffer”) by using a pistil. The homogenate 
was transferred into an Eppendorf tube and spinned at 12000 rpm for 10 
minutes at 4°C. The supernatant was transferred into a new tube without 
touching the pellet. 
The protein concentration per µl was determined by a Bradford assay. 
The protein samples were aliquoted and stored at -80°C.  
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2.1.19 In vitro stimulation of primary murine hepatocytes with            
murine HGF 
To proof the dysfunction of c-Met in c-MetΔhepa mice, c-MetloxP/loxp mice 
primary hepatocytes were isolated by using a multistep digestion protocol for 
the liver. To apply the digestion buffers to the liver, the inferior venae cava was 
canulated using a 22G catheter. After canulation, the portal vessels were cut to 
allow the flow through of buffers. The progress of the digestion was controlled 
by eye and the poking of the liver with forceps. The hepatocytes were released 
from the liver capsule by rupturing of the liver with forceps and shaking in the 
same time. 
To separate isolated hepatocytes from non-parenchymal liver cells, the 
total cells were centrifuged at 2000g for 3 minutes. To wash the cells, the pellet 
was resuspended in Williams-E medium three times and pelleted by 
centrifugation. After the last washing step, the pellet was resuspended in 10ml 
Williams-E medium. To determine the living cell ratio, the cells were stained 
with Trypan-Blue that selectively colours dead cells blue. The cells were 
counted in a Neubauer chamber and the total amount of isolated cells was 
determined according to the common Neubauer formula. 2,5x105 cells were 
incubated in Williams-E medium containing 1% glutamine and streptavidine on 
a six-well plate. 4 hours after isolation the medium was changed.  
For stimulation with murine HGF, primary hepatocytes were washed with 
PBS and covered with Williams-E-medium. 2µg/ml mHGF was added to the 
medium and incubated for 2 hours. After this, proteins were isolated directly 
from the cell culture dish by using 500 µl RIPA-buffer. 
 
2.1.20 Statistical analysis 
Data is presented as mean ± standard deviation. Statistical analysis was 
performed by using Microsoft Excel. The differences among two groups were 
validated by performing a two-sided, unpaired Student´s T-test. Differences 
were considered significant when the p-value was below 0,05. 
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2.2. Chemicals 
 
2.2.1 Chemicals  
 
Chemical Company, Location 
Agarose, (1→4)-3,6-Anhydro-α-L-galactopyranosyl- (1→3)-
β-D-galactopyranan (C12H18O9) 
Invitrogen, Karlsruhe 
APS, Ammonium persulfate (NH4)2S2O8) Roth, Karlsruhe 
Bovine Serum Albumine, BSA Sigma-Aldrich, Steinheim
β-mercaptoethanol, 2-Mercaptoethanol (C2H6OS) Applichem, Darmstadt 
BrDU (5-bromo-2-deoxyuridine) Signa-Aldirch, Steinheim 
Collagenase Type I Worthington/ Cell 
Systems, St. Katharinen 
Dry Milk Powder Applichem, Darmstadt 
EDTA (C10H16N2O8) Applichem, Darmstadt 
Ethanol, (CH3CH2OH) Fischar, Saarbrücken 
Eosin, 2′,4′,5′,7′-Tetrabromofluorescein (C20H8Br4O5) Sigma-Aldrich 
Ficoll 400 Sigma-Aldrich, Steinheim
Glucose (C6H12O6) Applichem, Darmstadt 
Glycin (C2H5NO2) Applichem, Darmstadt 
Haematoxylin (C16H14O6) according to Mayer Roth, Karlsruhe 
HEPES, 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (C8H18N2O4S) 
Roth, Karlsruhe 
Histol, Orange Terpenes Roth, Karlsruhe 
Hydrocloride (HCL) Applichem, Darmstadt 
Isopropanol, Propan-2-ol (C3H8O) Merck, Darmstadt 
Ketaminhydrochloride Ceva, Düsseldorf 
Methanol, (CH3OH) VWR, Darmstadt 
Monosodium phosphate (NaH2PO4) Roth, Karlsruhe 
MOPS, 3-(N-morpholino)propaesulfonic acid (C 7H15NO4S) Roth, Karlsruhe 
Orange G, (C16H10N2Na2O7S2) Roth, Karlsruhe 
Paraformaldehyde ((CH2O)n (n = 8 – 100)) Roth, Karlsruhe 
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Chemical Company, Location 
PIPES, piperazine-N,N′-bis(2-ethanesulfonic acid) 
(C8H18N2O6S2) 
Sigma-Aldrich, Steinheim
Polyacrylamide, poly(2-propenamide) (-CH2CHCONH2-) Roth, Karlsruhe 
Ponceau S, 3-Hydroxy-4-(2-sulfo-4-[4-
sulfophenylazo]phenylazo)-2,7-naphthalenedisulfonic acid 
sodium salt, (C22H12N4Na4O13S4) 
Sigma-Aldrich, Steinheim
Potassium chloride, (KCL) Merck, Darmstadt 
Sodium Dodecyl Sulfate (C12H25SO4Na) Roth, Karlsruhe 
Sodium fluoride, (NaF) Serva, Heidelberg 
Sodium Hydrogen Carbonate Roth, Karlsruhe 
Sodium hydroxide (liquid), (NaOH) KMF, Lohmar/VWR, 
Darmstadt 
Sodium hydroxide, (NaOH) (solid) Merck, Darmstadt 
Sodium-Azide (NaN3) Applichem, Darmstadt 
Sodium-orthovanodate (Na3VO4) Applichem, Darmstadt 
Sucrose,( C12H22O11) Merck, Darmstadt 
 
TEMED, Tetramethylethylenediamine 
((CH3)2NCH2CH2N(CH3)2) 
Serva, Heidelberg 
Tris (C4H11NO3) Applichem, Darmstadt 
Triton X-100, (C H O(C H O)14 22 2 4 n) (n=9-10) Serva, Heidelberg 
Tween 20, Polysorbate 20, (C58H114O26) Sigma-Aldrich, Steinheim
Xylazinhydrochloride Bernburg AG, Bernburg 
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2.2.2 Ready to Use Buffers 
 
Buffer Company, Location 
1x & 10x PBS, Phospho buffered saline PAA, Marburg 
10x SDS Running buffer Roth, Karlsruhe 
50x Tris-Acetate EDTA-Buffer, TAE-Buffer Gibco/Invitrogen, 
Karlsruhe 
EBSS w/o Ca2+ & Mg2+ Gibco/Invitrogen, 
Karlsruhe 
EBSS with Ca2+ & Mg2+ Gibco/Invitrogen, 
Karlsruhe 
Williams-E Medium Gibco/Invitrogen, 
Karlsruhe 
Antifect® N liquid desinfection Schuelke-Mayr, 
Norderstedt 
 
2.2.3 Antibodies 
 
Primary antibodies Company, Location 
anti-CK19 Santa Cruz, Heidelberg 
anti-STAT3 NEB, Frankfurt am Main 
anti-pSTAT3 NEB, Frankfurt am Main 
anti-STAT-1 NEB, Frankfurt am Main 
anti-pSTAT1 NEB, Frankfurt am Main 
anti-JNK NEB, Frankfurt am Main 
anti-pJNK NEB, Frankfurt am Main 
anti-Fas BD, Heidelberg 
anti-F4/80 Biotrend, Cologne 
anti-CD11b BD, Heidelberg 
anti-SMA Millipore, Schwallbach 
anti-pc-Met (pY1230;1234&1235) Sigma-Aldrich, Steinheim
anti-Ly6G BD, Heidelberg 
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Secondary antibodies Company, Location 
anti-goat HRP Dako, Hamburg 
anti-mouse Alexa 488 Invitrogen, Karlsruhe 
anti-mouse HRP Santa Cruz, Heidelberg 
anti-rabbit Alexa 488 Invitrogen, Karlsruhe 
anti-rabbit Alexa 546 Invitrogen, Karlsruhe 
anti-rabbit Alexa 594 Invitrogen, Karlsruhe 
anti-rabbit HRP NEB, Frankfurt am Main 
2.3 Buffers 
 
2.3.1 DNA loading buffer 
Ingredients Amount 
Ficoll Type 400 2,5g 
Orange G 100mg 
dH2O ad 10ml 
 
2.3.2 Tail lysis buffer 
 
Solution Volume (ml) 
1M Tris-HCl pH 8 2,5 
0,5 M EDTA pH 8 10 
1 M NaCl 5 
20% SDS 2,5 
H2O 30 
Total 50 
 
2.3.3 Tris buffered saline 
Ingredient Amount [g] 
Tris 121,14 
dH2O Approx. 800ml 
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For 1L of Tris-buffered saline (TBS) 1M Tris powder was solved in 800 ml 
dH2O and the pH was adjusted at 7,5 with HCL. Finally, the solution was filled 
up with dH2O up to 1L. 
2.3.4 Phosphate buffered saline 
Phosphate buffered saline (PBS) was purchased from Gibco® as a 10x 
Stock-solution, this Stock was diluted 1:10 in dH2O. 
 
2.3.5 Praraformaldehyde 
4% PFA was weight/volume up and solved in prewarmed 1x PBS. The 
final clear solution was adjusted at pH 7,4. Afterwards, the buffer was filtered, 
aliquoted and stored at -20°C. 
 
2.3.6 Whole Cell Protein Extraction Buffer 
 
Ingredient Volume 
3M NaCl 2,5 ml 
0,01 M EGTA 5 ml 
0,5 M EDTA pH8 100µl 
1M NaH2PO4 500 µl 
1M Tris pH 7,5 1 ml 
1M NaF 100 µl 
Triton X-100 500 µl 
0,1 M PMSF (in ETOH) 500 µl 
Proteinase Inhibitor Tabs 1 
1M Orthovanadate 50µl 
Total 10,25ml 
 
2.3.7 Blotting transfer buffer 
10x Stock 
Ingredient Amount [g] 
Tris 24,4 
Glycin 112,6 
dH2O ad 1L 
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1x Working solution 
 Ingredient Volume (176) 
10x Stock 100 
Methanol 200 
dH2O ad 1L 
 
 
 
 
 
2.3.8 RIPA buffer 
Volume Ingrdient 
5ml 1M Tris-HCL pH7,4 
30ml 5M NaCl 
5ml 20% NP-40 
5ml 10% Sodium deoxycholate 
0,5ml 20% SDS 
Ad 50ml ddH2O 
 
2.3.9 Buffers for isolation of primary hepatocytes 
 
Buffer1: 
EBSS w/o Ca2+ & Mg2+
0,5mM EGTA 
 
Buffer2:  
EBSS with Ca2+ & Mg2+
10mM Hepes 
pH adjusted at 7,4 
 
Buffer3: 
EBSS with Ca2+ & Mg2+
10mM Hepes 
pH adjusted at 7,4 
20mg Collagenase 
2mg Trypsin inhibitor 
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2.3.10 Primer-sequences: 
 
2.3.10.1 Genotyping-Primer (all primers are displayed in 5´-3´ direction) 
 
Target Annealing 
Temp 
Sequence 
pAlb-cre 62°C fwd: CGG GTG AAC GTG CAA AAC AGG CTC 
rev: CTT GCA TGA CCG GTA TTG AAA CTC CAG 
c-MetloxP/loxP 62°C fwd: AGC CTA GTG GAA TTC TCT GTA AG 
rev: CCA AGT GTC TGA CGG CTG TG 
gp130loxP/loxP 54°C fwd: GGC TTT TCC TCT GGT TCT TG 
rev: CAG GAA CAT TAG GCC AGA TG 
Met-KO cDNA  55°C fwd: TTC GGC AGA TTC CCA AGA G 
rev: TCA GGC AGA TTC CCA AGA G 
 
2.3.10.2 Real-Time PCR primers (all primers are displayed in 5´-
3´direction) 
 
Target Annealing 
Temp. 
Sequence 
α-SMA 60°C fwd: ATG AAG CCC AGA GCA AGA GA 
rev: ATG TCG TCC AGT TGG TGA T 
CD14 58°C fwd: CAG CCC TCT GTC CCC TCA A 
rev: TCT CCA TCC CCG CGT TAC 
Collagen 1α 60°C fwd: GGA AAC CTC TCT CGC CTC TT 
rev:  GAA CAG GGT GTT CCT GAG A 
CXCL2 59°C fwd: ACG GAA GAA CCA AAG AGA AAG AAA 
rev: CTC AGA CAG CGA GGC ACA TC 
Cytokeratin 19 (CK19) 60°C fwd: CGT ACC CCC AAA GGA AGA CA  
rev: TCA GAC CTG CGT CCC TTT TT 
GAPDH 60°C fwd: TGT TGA AGT CAC AGG AGA CAA CCT 
rev: AAC CTG CCA AGT ATG ATG ACA TCA 
HGF 60°C fwd: CCT GTC AGC GTT GGG ATT C 
rev: CTC GGA TGT TTG GGT CAG TGG 
ICAM-1 59°C fwd: GCC TTA GCA GCT GAA CAA TCG 
rev: CCT TCT AAG GAG TTG GAA CAT TTC C 
IL-1α 60°C fwd: TGG GAG CCC TTT CAT CAT GAT 
rev:  AAG GAC GGG AGG GAG AAA GAC T 
IL-1β 58°C fwd: GGA GAA CCA AGC AAC GAC AAA 
rev: GGG TGT GCC GTC TTT CAT TAC 
IL-10 60°C fwd: GTT GTG AAG AAA CTC ATG GGT CTT G 
rev: CTG AGC TGC TGC AGG AAT GAT C 
IL-11 59°C fwd: GGT GCA TCT GAG ACC CTG AAG 
rev: AAC AGA TTTC ATA GAG ACC CCA GAA C 
IL-4 59°C fwd:  GGA GAT GGA TGT GCC AAA CG 
rev:  AAT ATG CGA AGC ACC TTG GAA 
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Target Annealing 
Temp. 
Sequence 
IL-6 60°C fwd: CCG GAG AGG AGA CTT CAC AG 
rev: TCC ACG ATT TCC CAG AGA AC 
Interleukin-1 receptor 
activated kinase 4 
(IRAK4) 
58°C fwd: TCC ACA GCA ACA TCA CCA AAC T 
rev: CCC GCC CCA AAT AAT CCT A 
KC 59°C fwd: GTG TCC CCA AGT AAC GGA GA 
rev: TGC ACTTCT TTT CGC ACA AA 
LPS induced TNF 
alpha Facor t (LiTAF) 
58°C fwd: CTG CTT CAG TGC CGA GAG ATT 
rev: ACC ATG ATG ACC GTA CCA CAG A 
LPS-induced CXC-
Chemokine (LIX) 
59°C fwd: TGG ATC CAG AAG CTC CTG TGA 
rev: TGC ATT CCG CTT AGC TTT CTT T 
LPS-binding protein 
(LBP) 
59°C fwd: GCA TCC AGA CAA GGC ACA AGT 
rev: GAA TGC CTG GAA CAG GTT CAC 
Matrix metallo-
proteinase 13 
(MMP13) 
60°C fwd: CCT GAT TCT TGC GTG CTA TGA A 
rev: CAG ATG GAC CCC ATG TTT GC 
Myloid response 
protein 88 (MyD88) 
58°C fwd: CAT GGT CCC TCT CAG GGT ACA C 
rev: CTC ATT CCT CCC CCA GAC ACT 
Oncostatin M 58°C fwd: ACT CTG ACA TAG GGT GGA CAT CAA 
rev: CCC CAC AAC CGT TTG CA 
Platelet derived 
growth factor D 
(PDGF-D) 
58°C fwd: AAT GCA GTC TTC TTC CCA CGA T 
rev: CAG TTC CGC AAC CAC AGT TG 
Serum Amyloid A 
(SAA) 
60°C fwd: TCT CTG GGG CAA CAT AGT ATA CCT CTC 
         AT 
rev: TTT ATT ACC CTC TCC TCC TCA AGC AGT     
        TAC 
Supressor of Cytokine 
Signalling-1 (SOCS-1) 
59°C fwd: CCT GGT TGT AGC AGC TTG TGT CT 
rev: CCC CTG GTT TGT GCA AAG ATA C 
Supressor of Cytokine 
Signalling-3 (SOCS-3) 
59°C fwd: GAA CCC TCC CCG TTG TGA A 
rev: CCC TTC GGT GTT GGA AAA GG 
TGF-β1 59°C fwd: AAA AAC CAA AGC CCA AAA AGC TA 
rev: ATG ACT CAC ACT GAC GCA GAA AA 
Tissue inhibitor of 
metallo-proteinase-1 
(TIMP-1) 
60°C fwd: AGT CCC AGA ACC GCA GTG AA 
rev: AGA GTA CGC CAG GGA ACC AA 
TNF-α 60°C fwd: CAT TCG AGG CTC CAG TGA ATT C 
rev:  GAA ACA CAA GAT GCT GGG ACA GT 
TNFAIP2 58°C fwd: AGC AAG GTG GAG GGC TCT GTA 
rev:  GAA GCT CCT GTG CCA ACT TC 
Toll-like Receptor 4 
(TLR4) 
59°C fwd: GCC TTT CAG GGA ATT AAG CTC C 
rev:  AGA TCA ACC GAT GGA CGT GTA A 
toll-interleukin 1 
receptor domain 
containing adaptor 
protein (Tirap) 
59°C fwd:  CCG TGG TAG GCT TGC TTA GC 
rev: GGT TTG TGT TTT CTC CTT TGT TTT G 
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2.4 Equipment: 
 
2.4.1 Glasware 
Beakers (10 – 1000 ml) Schott-Duran, Mainz 
Bottles (25- 2000 ml) Schott-Duran, Mainz 
Capillaries for blood taking Hirschmann Laborgeräte, 
Eberstadt 
Slides for immunflourescence, SuperFrost Roth 
Pasteur pipettes Brand, Giessen 
 
2.4.2 Plasticware 
 
96-well plates for RNA/DNA measurement Greiner Bio-one, Frickenhausen 
96-well plates for protein measurement Greiner Bio-one, Frickenhausen 
96-well plates for Real-Time PCR StarLab, Ahrensburg 
Pipettes tips with filter for liquid handling VWR, Darmstadt; BioHit, 
Rosbach v.d. Höhe; Biozym, 
Hess. Oldendorf 
Reactionstubes (0,5 – 2ml) Eppendorf, Hamburg 
8 vial strips for PCR (0,2ml) Sarstedt, Nümbrecht 
Reactiontubes 15ml Sarstedt, Nümbrecht 
Reactiontubes 50 ml GreinerBio-one, Frickenhausen 
Sterile pipettes (2-50ml) Sarstedt, Nümbrecht 
Cryotubes 1,5 ml Nunc, Langenselbold 
6; 12; 24-well plates BD-Falcon, Heidelberg 
 
2.4.5 Microscope: 
AxioImager Z1 Carl Zeiss, Jena 
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2.4.6 Thermocycler 
T3000 Thermocycler Biometra, Göttingen 
7300 Real-Time PCR System Applied Biosystems, Darmstadt 
 
2.4.7 Centrifuges 
Eppendorf Tabletop 5417 Eppendorf, Hamburg 
Heraeus-Kendro Megafuge 1.0R Thermo Scientific, Dreieich 
 
2.4.8 Mixer & Vortexer 
CAT RM5 Novodirect, Kehl am Rhein 
Vortex Genius 3  IKA, Staufen 
 
2.4.9 Cell Incubator 
Haereus BB 6220 Thermo Scientific, Dreieich 
 
2.4.10 Cell culture bench 
BSB6A Gelaire Flow Laboratories, 
Meckenheim 
 
2.4.11 Cryotome 
HM 550 Cryostat Microm Thermo Scientific, Dreieich 
 
2.4.12 Gel chambers 
Subcell GT Biorad, München 
Minigel Twin Biometra, Göttingen 
Multigel Biometra, Göttingen 
 
2.4.13 Blotting chamber 
Trans-Blot cell Biorad, München 
Semi-Dry-blotter MAXI Carl-Roth GmbH, Karlsruhe 
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3. Results 
 
3.1 Involvement of c-Met during hepatic fibrosis 
development and antiapoptotic signalling  
3.1.1 Embryonic hepatocyte specific c-Met deletion is lethal 
 
The first aim was to generate hepatocyte specific c-Met conditional knockout 
animals.  
 
 
Figure 10: Generation and characterisation of a hepatocyte-specific c-Met knockout 
mouse  A) Strategy for the hepatocyte-specific deletion of c-Met. In c-MetloxP/loxP mice the 
coding region for the transmembrane domain (exon 15) is flanked by two loxP sites. c-
MetloxP/loxP mice were either crossed with animals expressing the Cre-recombinase under the 
control of an albumin/AFP promoter/enhancer construct (Alfp-Cre, prenatal Cre expression) 
or under the control of an albumin promoter construct (Alb-Cre, postnatal Cre expression). 
While Alfp-Cre(+)/c-MetloxP/loxP animals died during embryonal development Alb-Cre(+)/c-
MetloxP/loxP (c-Methepa) mice were viable at normal mendelian frequency B) Deletion of c-Met 
exon 15 was tested by RT-PCR. Liver RNA or RNA from isolated hepatocytes derived from 
either c-MetΔhepa or c-MetloxP/loxP mice were tested via a PCR protocol using primers that are 
able to detect deletion of exon 15 in the c-Met gene. The position of the deleted (Δc-Met) 
and the undeleted DNA (wt c-Met) are indicated. Intensity of bands was evaluated 
densitometrically. C) HGF induces phosphorylation of c-Met in hepatocytes. Primary 
hepatocytes were isolated by liver perfusion, plated overnight and stimulated with 10ng/µl 
HGF for 30min. Immunoblot analysis displayed c-Met phosphorylation (pY1230/1234/1235) in c-
MetloxP/loxP mice, while this regulation was blunted in c-MetΔhepa mice. As protein loading 
control α-tubulin staining was performed. 
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C-MetloxP/loxP animals were crossed with transgenic animals expressing the Cre-
recombinase under the control of an Albumin/AFP promoter/enhancer (Alfp-Cre) 
construct. Earlier results demonstrated that this construct results in efficient 
target gene deletion in hepatocytes at day 12 during embryonic development 
(77). Interestingly, crossbreeding of c-MetloxP/loxP animals with Alfp-Cre(+/-)/c-
MetloxP/wt mice did not result in the generation of hepatocyte specific c-Met 
knockout animals as no viable Alfp-Cre(+)/c-MetloxP/loxP mice were born (Fig. 
10A). This supports prior findings (21) that the HGF/c-Met system in 
hepatocytes is essential for normal mouse embryonic development. As an 
alternative strategy an albumin promoter Cre construct (Alb-Cre) expressing 
Cre-recombinase in hepatocytes only after birth was used. This strategy was 
successful in generating a hepatocyte specific c-Met knockout mouse line (c-
MetΔhepa). Offsprings of c-Met∆hepa and c-MetloxP/loxP animals were born in a 
normal Mendelian frequency (Fig 10A) and showed a deletion efficiency of c-
Met in hepatocytes of more than 95% (Fig. 10B). The functional effect of this 
deletion was further evidenced by demonstrating the lack of c-Met 
phosphorylation in primary hepatocytes derived from c-Met∆hepa mice (Fig. 10C). 
 
3.1.2 Hepatocyte specific deletion of c-Met results in enhanced 
necrosis and fibrosis after bile duct ligation 
Bile duct ligation was performed in c-Met∆hepa and c-MetloxP/loxP (controls) mice in 
order to test the relevance of c-Met signalling in a model of chronic liver injury. 
All control mice survived the first 4 weeks after BDL, while 12,5% of c-Met∆hepa 
animals died during this time period (Fig. 11A). Serum transaminases increased 
after BDL in both groups (Fig. 11B), while 4 weeks after BDL a strong and 
significant decrease in serum protein levels was found in c-Met∆hepa mice 
compared to the control group (Fig. 11C). At least 10 view-fields/liver in four 
animals of each group were included. Significantly more necrotic areas were 
found in the livers of c-MetΔhepa mice compared to c-MetloxP/loxP controls. 
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Figure 11: Changes in serum parameters and liver histology in c-MetΔhepa mice after bile 
duct ligation (A) Kaplan-Meyer-analysis of mouse survival after BDL. All c-MetloxP/loxp mice 
survived BDL (n=8), while 88% of c-MetΔhepa mice survived (n=8). (B) Serum ALT levels were 
strongly and significantly elevated up to 28 days after BDL. No significant differences were 
found between c-MetΔhepa and c-MetloxP/loxP mice.(C) Total protein in mouse serum 28d after BDL. 
C-MetΔhepa mice showed a significantly reduced amount of total serum protein (*=p<0,05).(D) 
H&E stainings of paraffin-embedded liver sections of c-MetΔhepa and c-MetloxP/loxP mice before, 7 
and 28 after BDL (10x magnification). Necrotic areas which are most apparent in c-MetΔhepa 
mice are indicated by arrows. (E) Quantification of necrotic areas 3 and 7 days after BDL. 
(*=p<0,01). 
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3.1.3 Enhanced inflammatory response and immune cell 
infiltration after bile duct ligation in c-MetΔhepa mice 
 
 
Figure 12: c-MetΔhepa mice show an enhanced inflammatory response after bile duct 
ligation A-C) TNF-α, IL-6 and HGF expression were quantified by real-time PCR at indicated 
time points before and after bile duct ligation. RNA was extracted seperately from individual liver 
tissues (at least 4 samples/timepoint were included) at the respective timepoints (*=p<0,05, 
**=p<0,01) D,E) KC (Gro-α) chemokine expression was analysed by real-time PCR and Elisa. 
Significant differences in KC liver mRNA and serum levels are indicated between c-MetΔhepa-
mice and controls (*=p<0,05, **=p<0,01). 
 
To better characterise the impact of c-Met deletion on liver injury, H&E 
stainings of liver sections were performed. In c-Met∆hepa mice significantly more 
necrosis (higher numbers and larger areas) was found 3 and 7 days after BDL 
compared to c-MetloxP/loxP controls (Fig. 12D, E). The significantly more 
prominent effect on necrosis in livers of c-Met∆hepa animals after BDL prompted 
us to investigate the underlying mechanisms. 
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Figure 13: c-MetΔhepa mice display a stronger recruitment of immune cells to the liver A, B) 
Cryosections were immunostained to display the infiltration of Ly6G(+) neutrophils (A) and 
F4/80(+) macrophages (B). c-MetΔhepa mice show a significantly higher number of either cell 
population compared to c-MetloxP/loxP animals. A statistical anlysis is provided under the panels 
(C) and (D). C is for the Ly6G+ neutrophils and D is for the F4/80+ macrophages  
 
Real-time PCR analysis of proinflammatory cytokines revealed in c-
Met∆hepa mice a 3-4 fold higher expression of Tumour Necrosis Factor-alpha 
(TNF-α) mRNA and a tenfold elevation of Interleukin-6 (IL-6) mRNA compared 
to controls (3 and 7d after BDL, Fig. 13 A, B). Additionally, HGF mRNA levels 
were significantly higher expressed in c-Met∆hepa mice. The increased 
expression of proinflammatory cytokines in livers of c-Met∆hepa mice after BDL 
correlated with the stronger occurrence of necrotic lesions and cellular infiltrates. 
Significantly higher amounts of Ly6G(+) neutrophils and of F4/80(+) 
macrophages were found in livers of c-Met∆hepa mice after BDL (Fig. 12D, E, 
and Fig. 13A, B). Quantification revealed a significant twofold higher amount of 
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both infiltrating cell types in c-Met∆hepa livers compared to controls. As the CXC 
chemokine KC (Gro-α, IL-8) is known to be involved in the recruitment of 
neutrophils (177), KC expression after BDL was analysed. In livers of c-Met∆hepa 
mice stronger KC mRNA expression was be detected 3 days after BDL (Fig. 
12E). This observation was be confirmed at the protein level showing 
significantly higher KC expression at 3 and 7 days after BDL in c-Met∆hepa mice. 
 
3.1.4 Enhanced apoptosis and an impaired proliferative 
response in c-Met∆hepa mice after BDL  
 
 
Figure 14: Higher apoptosis rates and decreased proliferation in livers of c-MetΔhepa mice 
after BDL (A) Apoptotic cells were analysed by TUNEL staining (green) in livers of c-MetΔhepa 
and c-MetloxP/loxP controls before and after BDL as indicated. Representative pictures are shown 
for each time point. (B) Statistical analysis of TUNEL positive cells in livers of c-MetloxP/loxP 
controls and c-MetΔhepa mice after BDL (*=p<0,05). At least 10 view fields of 4 livers per time 
point were included in this analysis. (C) Hepatocyte proliferation was analysed by BrdU uptake 
in livers of c-MetloxP/loxP controls and c-MetΔhepa mice before and after BDL. Anti-BrdU antibodies 
were labelled with Alexa488 (green). (D) Statistical analysis of BrdU positive cells in livers of c-
MetloxP/loxP controls and c-MetΔhepa mice before and 7 days after BDL (*=p<0,05). At least 10 view 
fields of 4 livers per time point were included in this analysis. 
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After finding a higher degree of injury and a stronger inflammatory 
response in livers of c-Met∆hepa mice after BDL, the impact of these findings on 
apoptosis and proliferation in these mice compared to controls was studied next. 
TUNEL analysis of bile duct ligated livers revealed an increase in the number of 
apoptotic cells with a significant enhancement in livers of c-Met∆hepa mice over 
the whole time course after BDL compared to the control group (Fig. 14A, 
B).The HGF/c-Met system is a known critical regulator of hepatocyte 
proliferation (13). Analysis of cell cycle progression unravelled a significant 
reduction of BrdU positive hepatocytes in livers of c-Met∆hepa mice 7d after BDL 
(Fig. 14, D). The rate of proliferating hepatocytes decreased at 28d after BDL 
and did not differ between both groups at this timepoint.  
 
3.1.5 Microarray analysis identifies a cluster of c-Met-
dependent regulated anti-apoptotic genes  
 
 
Figure 15: HGF Stimulation activates STAT3 in the liver A) C-MetloxP/loxP and c-MetΔhepa mice 
were stimulated with 2µg recombinant mouse HGF. Total protein was isolated and Western Blot 
analysis for the detection of phosphorylated STAT3 was performed. The position of phospho-
STAT3 (pSTAT3) is indicated. B) For gene array analysis c-MetloxP/loxP controls were stimulated 
for 2 hours with 2µg recombinant mouse HGF. Liver RNA was isolated from animals before and 
after HGF stimulation. Detailed analysis of gene expression unravelled a set of 463 genes in 
total being up- or downregulated more then twofold by HGF/c-Met (limma p-value < 0.01). C) 
Affymetrix GeneChip analysis of liver RNA was used to detect gene expression of HGF–
stimulated c-MetΔhepa and c-MetloxP/loxP mice. Three animals per group were treated in parallel, 
before and after i.p. injection of recombinant HGF or NaCl. Examples of genes that are 
regulated HGF/c-Met-dependent and are cell-damage and apoptosis related are depicted. 
gcRMA normalised intensity values are provided before and after treatment with corresponding 
fold changes and limma p-values. Microarray data can be found under GEO series accession 
number GSE13992. 
 
The phenotype showing stronger liver injury with enhanced apoptosis in c-
Met∆hepa mice after BDL stressed the question to better define the molecular 
mechanisms explaining our observation. In order to identify potential genes 
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responsible to confer HGF/c-Met-dependent protection, microarray analysis was 
performed. Recombinant HGF was injected into c-Met∆hepa and control mice 
liver. 
 
Table 3: Affymetrix GeneChip analysis of liver RNA was used to detect gene expression of 
HGF–stimulated c-MetΔhepa and c-MetloxP/loxP mice. Three animals per group were treated in 
parallel, before and after i.p. injection of recombinant HGF or NaCl. Examples of genes that are 
regulated HGF/c-Met-dependent and cell-damage and apoptosis related are depicted. gcRMA 
normalised intensity values are provided before and after treatment with corresponding fold 
changes and limma p-values. Microarray data can be found under GEO series accession 
number GSE13992. 
 
mRNA was isolated before and after stimulation to perform whole mouse 
genome arrays (AffymetricsTM). STAT3 phosphorylation was tested in livers of 
control and c-Met depleted mice before and after HGF stimulation (Fig. 15A) to 
analyse this downstream target. While control mice displayed a strong STAT3-
phosphorylation after HGF-stimulation, this reaction was almost blunted in c-
Met∆hepa mice. 
Array analysis (GEO series accession number: GSE13992) defined a set 
of 463 genes (Fig. 15B), that have been positively or negatively regulated 
through HGF by more then twofold (limma p-value < 0.01) in c-MetloxP/loxP mice 
(Table 3).  
In contrast, only four genes were significantly regulated in c-Met∆hepa mice 
(Fig. 15B). In addition, we identified 79 genes that are differentially expressed 
between c-MetloxP/loxP and c-Met∆hepa mice (Fig 15B).  
A cluster of genes that was be potentially involved in mediating HGF-
dependent apoptosis protection was found. Within this cluster, genes like 
Gadd45α, β and γ (growth arrest and DNA damage-inducible, a gene family 
involved in cell cycle progression and apoptosis regulation), Fas, Bcl3, 
TNFAIP3 (also known as A20) and TNFAIP2 (know as B94) as strictly c-Met 
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regulated genes (Fig. 16C) were identified. As shown for TNFAIP2 a significant 
6-fold induction was found in livers of c-MetloxP/loxP mice after BDL, while 
practically no regulation of TNFAIP2 was detected in c-Met∆hepa mice (Fig. 16A). 
Gene array analysis and increased apoptosis rates after BDL in c-Met∆hepa livers 
suggested that HGF via c-Met is essential to mediate anti-apoptotic signals. The 
Fas/Fas-L system is an important pathway to trigger apoptosis of hepatocytes 
tested if c-Met∆hepa livers are more susceptible to Fas-induced apoptosis after 
BDL was tested. 
 
 
Figure 16: c-MetΔhepa mice are hypersensitive to FAS-induced apoptosis (A) TNFAIP2 
expression was quantified by real-time PCR before and 3 days after bile duct ligation as 
indicated. RNA was extracted separately from individual liver tissues (at least 4 samples/time 
point were included) at the respective time points (*=p<0,05). (B) Bile duct ligated mice were 
stimulated 3 d after BDL with Jo-2 (6 hours) antibody (400ng/g bodyweight). c-MetΔhepa mice 
displayed significantly higher counts of TUNEL positive cells (F). (C) Statistical analysis of 
TUNEL positive cells in c-MetloxP/loxPcontrols and c-MetΔhepa in 3d bile duct ligated mice, that 
were stimulated for 6h with Jo-2 antibody (*=p<0,05). At least 10 view fields of 4 livers per time 
point were included in this analysis. 
 
Therefore, BDL was performed in c-Met∆hepa and c-MetloxP/loxP mice and after 3 
days animals were stimulated for 6 h with Jo-2 antibody. In the livers of c-
Met∆hepa mice significantly more apoptotic cells was be detected (Fig 16B). 
Quantitative analysis revealed that in this setting c-Met∆hepa mice showed twice 
as many apoptotic cells compared to simply bile duct ligated animals, while 
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control MetloxP/loxP mice displayed only a modest increase in the number of 
apoptotic cells after additional Jo-2 stimulation (Fig. 16C). 
 
3.1.6 Bile duct ligation triggers earlier and stronger hepatic 
stellate cell activation in c-Met∆hepa livers 
 
BDL in rodents causes irreversible cholestases, which triggers hepatic 
stellate cell activation (HSC) and thus fibrogenesis.  
 
 
Figure 17: c -Met deletion in hepatocytes induces enhanced stellate cell activation after 
BDL (A, B, D) TGF-β, TLR4 and α-SMA expression were quantified by real-time PCR at time 
points before and after bile duct ligation as indicated. RNA was extracted separately from 
individual liver tissues (at least 4 samples/time point were included) at the respective time points 
(*=p<0,05, **=p<0,01). Analyses for c-MetΔhepa and c-MetloxP/loxP controls are shown. (C) 
Immunoflourescence analysis of α-SMA-expression (Alexa488 green) in livers of bile duct 
ligated c-MetΔhepa and control mice before and 3 days after BDL, indicating a stronger activation 
of HSCs in c-MetΔhepa mice that underwent BDL, are displayed. Representative pictures are 
shown for each timepoint. 
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We found substantially more necrosis and apoptosis after BDL in c-
Met∆hepa mice, whether this observation had an impact on fibrosis progression 
by studying the activation of profibrogenic markers was investigated. First, TGF-
β1 expression – one of the main growth factors mediating HSC activation – was 
analysed. TGF-β1 mRNA expression was strongly induced already 3d after BDL 
in both groups (Fig. 17A), showing a significantly higher induction in c-Met∆hepa 
mice (up to 26-fold). In parallel, expression of TLR4, which is also expressed on 
HSCs and is involved in triggering stellate cell activation and thus fibrosis (111), 
was increased in livers of c-Met∆hepa animals (Fig. 17B). 
This observation was associated with a twofold higher mRNA expression 
of the HSC activation marker alpha-smooth muscle-actin (α-SMA) in c-Met∆hepa 
livers after BDL. These results were further confirmed on the protein level by α-
SMA specific immunoflourescence studies (Fig. 17C, D). 
 
3.1.7 Bile duct ligation results in more liver fibrosis in c-Met∆hepa 
mice 
Next, fibrosis progression was investigated by performing sirius red 
stainings using polarised light to detect collagen accumulation as a marker of 
fibrosis progression. Morphometric quantification of liver tissue from the 4 week 
post-BDL time point demonstrated a significantly stronger sirius red staining in 
livers of c-Met∆hepa mice compared to the c-MetloxP/loxP control group (Fig. 18A, 
B). This finding was further strengthened by a twofold enhanced collagen-1α-
mRNA expression (Fig. 18C). Also matrix modulating enzymes MMP-13 and its 
antagonist TIMP-1 mRNA-levels were found to be upregulated nearly twofold in 
c-Met∆hepa mice compared to BDL-treated control animals (Fig. 18D, E). The 
profibrotic factor PDGF-D, which was recently shown to be directly involved in 
BDL-induced fibrosis progression (178), was also strongly enhanced in its 
expression level in c-Met∆hepa mice (Fig. 18F). 
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Figure 18: Enhanced progression of liver fibrosis in c-MetΔhepa mice after BDL (A) Sirius 
red staining of paraffin embedded liver tissue derived from livers of c-MetΔhepa and c-MetloxP/loxP 
controls 28 days after BDL. Representative photomicrographs taken under polarized light are 
shown for each time point (200x magnification). (B) Graphical analysis of liver Sirius red staining 
in c-MetΔhepa mice and c-MetloxP/loxP controls 28 days after BDL. To graphically visualize the 
difference in collagen fiber accumulation, the intensity of sirius red staining in bile duct ligated 
mice (as shown in figure 6 A) was determined. Photomicrographs of Sirius red stained slides 
were analysed using the open source ImageJ software (livers from non bile duct ligated mice 
were used as controls and set as zero, **=p<0,01). Collagen-1α (C), MMP13 (D), TIMP-1 (E) 
and PDGF-D (F) expression was quantified by real-time PCR before and 28 days after bile duct 
ligation as indicated. RNA was extracted seperately from individual liver tissues (at least 4 
samples/time point were included) at the respective time points (*=p<0,05).  
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Figure 19: Bile duct ligation causes stronger proliferation of bile ducts in c-MetΔhepa mice 
(A) Cytokeratin-19 (CK-19) immunoflourescence staining (Alexa488 green) in livers of bile duct 
ligated c-MetΔhepa and control mice before and 3 days after BDL were performed. 
Representative pictures are shown for each time point. Analyses for c-Methepa and c-MetloxP/loxP 
controls are shown. (B) Statistical analysis of CK-19 positive cells in 28d bile duct ligated c-
MetloxP/loxP controls and c-MetΔhepa mice are shown (*=p<0,05). 
 
Chronic liver injury can also trigger the proliferation of biliary epithelial and liver 
progenitor cells. As lack of c-Met expression was associated with more 
pronounced liver damage, we investigated the expression of Cytokeratin-19 
(CK19) after BDL in both groups on the mRNA and protein level (Fig. 19 A, B).  
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3.2 c-Met and gp130 mediated signalling during the 
acute phase response after BDL 
3.2.1 Decreased survival of mice deficient in gp130 after BDL 
The ligation of the common bile duct results in an afflux of the bile acid in 
the bile ducts and bulging of the gall bladder. This causes damage to liver cells, 
e.g. hepatocytes, and the bile ducts itself. 
To analyse the acute phase response induced after BDL in more detail, 
in addition to the c-MetΔhepa mice also gp130 and c-Met/gp130Δhepa double 
knockout mice were generated to investigate a molecular connection between 
c-Met and gp130 signalling pathways during the acute phase response. 
Because HGF and c-Met was already described as a modulatory component of 
the acute phase, c-MetΔhepa and c-Metgp130Δhepa mice were generated and 
used for this analysis. Previous investigations reported that a lack of the acute 
phase response promted the development of increased hepatocellular injury in 
several other liver injury models (74-77, 87, 163).  
Analysis of the survival rate during this early phase of injury revealed a 
dramatic mortality of c-Met/gp130 deficient mice and gp130Δhepa-mice (Fig. 20). 
C-Met/gp130 double deficient mice mostly died between 2 and 5 days post BDL.  
  
 
Figure 20: Survival during early phase of BDL The survival of the acute phase after BDL is 
displayed as a Kaplan-Meyer curve. It demonstrates that c-MetΔhepa mice and control mice 
survive the first period of 7 days post BDL without complications. In contrast to that, gp130 and 
c-Met/gp130 deficient mice strains show an increasing mortality at earlier time. 
 
In contrast to this, c-Met/gp130loxP/loxP and c-MetΔhepa mice survived 
without a case of death during the experimental course. Gp130Δhepa displayed 
the first BDL-related death at day 4 and further at day 5 and 6. The total 
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numbers of surviving gp130-deficient mice was around 50% for c-
Met/gp130Δhepa mice and 37,5% for the gp130Δhepa mice, whereas 100% of the 
c-MetloxP/loxP and c-MetΔhepa mice survived the early phase after bile duct ligation. 
Long term BDL for about 28 days revealed that c-Met/gp130Δhepa mice 
displayed further deaths, thus lowering overall survival to 25%. The gp130-
deficient mice displayed no mortality at later time points. 
 
3.2.2 Changes in serum parameters during the early phase after 
BDL 
In order to investigate the physiological response of the mice to BDL, 
serum parameters of liver function like bilirubin and the transaminase ALT were 
measured. In general only in a very low amount of Bilirubin is detectable in the 
serum, because it is catabolized in the liver. Higher levels of bilirubin are an 
indication for a dysfunction of the liver. The same is the case for ALT. In a case 
of severe liver injury, an increase of the alanine transaminase is detectable.  
 
 
Figure 21: Analysis of serum parameters during the acute phase reaction The grade of 
liver injury can be indicated by measuring key factors in the serum of the mice which were used 
for BDL. Bilirubin and the liver specific transaminase ALT were measured at day 0 and 3 after 
BDL and the changes are shown in (A) and (B)  
 
All genotypes displayed an at least 15-fold higher value of Bilirubin at day 
3 after BDL. AST level increased at least 5-fold in all mice where were 
submitted to BDL at the 3rd day after BDL (Fig. 21 A, B), thereby not differing 
among individual genotypes.  
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3.2.3 Histological analysis after BDL 
 
 
Figure 22: Histological investigation of the acute liver injury induced by BDL The 
histological changes at day 3 after BDL in the liver of all genotypes were analysed by H&E 
staining.  
 
The changes in liver architecture were analysed by an evaluation of 
Hematoxylin & Eosin (H&E) stainings of paraffin embedded liver samples. The 
mice deficient for either c-Met or gp130 displayed an almost equal degree of 
liver injury at day 3 post BDL. The amount of bile infarcts/necrotic areas was 
statistically equal among the c-MetΔhepa and the gp130Δhepa, but significantly 
higher compared to their littermate controls (Fig 22 & Fig 23). In comparison to 
this, c-Met/gp130-deficient mice displayed the strongest phenotype of liver 
injury after early timepoints. 
 
 
Figure 23: BDL causes higher degree of necrosis in gene deficient mice The statistic 
evaluation of the necrotic areas after the BDL at the timepoint 3d after BDL #=p<0,0001. 
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These mice also had the highest rate of necrotic areas detectable. Although the 
highest numbers of inflammatory cells was observed at day 3 after BDL in c-
Met/gp130Δhepa mice.  
 
 
Figure 24: Tunel staining reveals a higher degree of apoptosis in the liver after BDL 
Displayed are representative picture of a TUNEL staining after BDL from cre-negative and the 
indicated knockout strains. Pictures were taken in 200x magnification. Nuclei were 
counterstained with DAPI and FITC was used for TUNEL-labelling. 
 
TUNEL assay was used to analyze the induction of apoptosis (Fig. 24). 
This assay unravelled a significant higher percentage of DNA-strand brakes in 
c-MetΔhepa mice compared to c-MetloxP/loxP mice at day 3 after BDL post bile duct 
ligation. At day 3 post BDL the gp130Δhepa mice showed a higher number of 
TUNEL-positive cells compared to control littermates, but without a significant 
difference (Fig. 25).  
Figure 25: Statistical analysis of apoptosis in the acute phase of the BDL Displayed are 
the relative percentages of cells positive for apoptosis in the Tunel-assay 3 days after BDL as 
indicated. The rate was calculated by Tunel-positive nuclei versus total DAPI-stained nuclei. Per 
each genotype and timepoint, at least 3 mice were analysed and at least 7 high power view 
fields were analysed (*=p<0,05). 
 62
3. Results 
The c-Met/gp130Δhepa mice displayed the highest number of TUNEL-positive 
cells 3 days after BDL (Fig. 24 & Fig. 25).  
 
3.2.4 Bacterial load after Bile Duct Ligation 
During BDL, the liver is not only challenged by the injury of bile acids. To 
determine the bacterial load, a colony forming unit assay was performed using 
total liver extracts and peripheral blood as described in section 2.1.16 and 
2.1.17. 
 
 
Figure 26: Detailed analysis of the bacterial load Analysis of bile duct ligated mice showed 
an increased cfu/ml in peripheral blood and liver after BDL (A and B) *=p<0,05; **=p<0,01; 
#=p<0,0001. 
 
C-Met/gp130loxP/loxP mice had the lowest number of total cfu after BDL at 
day 3, no cfu were detectable in the liver and only a low number of bacteria was 
detectable in the peripheral blood. 5x104 cfu/ml were found in the homogenate 
of c-Met deficient livers (Fig. 26A) and about 2x104 cfu/ml were found in the 
blood of the c-MetΔhepa mice. The highest number of cfu in blood (1x105) and 
liver (1,8x105) was detected in c-Met/gp130Δhepa mice (Fig. 26B). Compared to 
c-MetΔhepa mice the gp130Δhepa animals displayed a significantly lower number of 
cfu in the liver and an almost equal quantity of cfu in blood as the c-MetΔhepa 
mice.  
This prompted to further analyse different components of the antibacterial 
signalling like LPS-binding protein, its co-receptor CD14 and the Toll-like-
receptor 4, which is involved in anti-inflammatory signalling. Those were 
analysed by quantitative Real-Time PCR at day 3 after BDL. This analysis 
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displayed a strong expression of CD14 mRNA in c-Met/gp130loxP/loxp mice and 
gp130Δhepa mice. The c-Met and c-Met/g130Δhepa mice did not express such a 
strong amount of CD14 (Fig. 27A). 
 
 
Figure 27: Analysis of the antibacterial response after BDL The investigation of components 
of the antibacterial response showed an differentially expression of the key-molecules CD14 
and LBP in all knockout animals compared to the WT-mice (A, B). mRNA-Expression of 
components of the antibacterial signalling and LiTAF (C ) and LIX (D) were analysed by Real-
Time PCR at day 3 after BDL as indicated  *=p<0,05; **p<0,01. 
 
The mRNA-expression analysis for the LPS-binding protein (LBP) 
revealed the strongest expression levels in c-MetΔhepa mice, whereas control-
mice and both gp130Δhepa mice-strains showed only a moderate induction (Fig. 
27B). Further components of the antibacterial LPS-induced signalling are the 
recently discovered transcription factor LPS induced TNF-alpha factor (LiTAF) 
(179). Its expression was less strong induced in the gp130Δhepa and in the c-
Met/gp130Δhepa mice, whereas the control mice and the c-MetΔhepa-mice did not 
show an activation of mRNA expression of this factor (Fig. 27C). The LPS 
induced CXC-chemokine LIX, which is also recruiting neutrophils such as KC 
(see section 3.2.4) (180), was significantly higher expressed in c-MetΔhepa mice 
and c-Met/gp130Δhepa mice compared to wt and gp130-deficient mice (Fig. 27D).  
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Regarding the results from the cfu assay of the liver (Fig. 26A), the mRNA 
expression of LIX fits together with the detected numbers of bacteria. 
 
Figure 28: Analysis of the Toll-like receptor sigalling Real-Time PCR analysis of the 
expression of the LPS- Receptor TLR4 (A) and its signalling transducers MyD88 (B) and Tirap 
(C) as well as the downstream kinase Irak4 (D). mRNA expression was compared to GAPDH as 
a housekeeping gene. 
 
Toll-like-receptor 4 is also involved in the antibacterial signalling, TLR4 is 
activated, among other stimuli, by LPS (181). The expression of TLR4 mRNA 
was significantly stronger induced in c-MetΔhepa and c-Met/gp130Δhepa as well as 
in the gp130Δhepa mice compared to the control animals at day 3 after BDL (Fig. 
28A). 
Interestingly, the signalling transduction factor MyD88, which is important 
for mediating TLR4 signalling, was significantly reduced in all gp130Δhepa mice 
strains in comparison to c-MetΔhepa mice (Fig. 28B). Whereas MyD88 is also 
used by the IL-1 receptors for signalling transduction, Tirap, a TLR4 specific 
signalling transducer, was significantly downregulated (Fig. 28C) in c-MetΔhepa, 
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gp130Δhepa and c-Met/gp130Δhepa mice . Another analyzed factor in the TLR4 
signalling cascade was the Interleukin-receptor-1-associated kinase 4 (Irak4). It 
is known to be involved in phopshorylation and activation of proteins such as 
JNK or NFκB. Its expression was only shown to be induced in c-MetloxP/loxp (Fig. 
28D). 
 
3.2.5 Dissection of the acute phase response 
An important mediator of the acute phase response is the IL-6-gp130-
STAT3-axis. An imbalance in its regulation has massive consequences for the 
homeostasis of liver cells, the organ and finally the organism itself. Detailed 
analysis unravelled a diminished STAT3 activation in c-MetΔhepa mice and an 
almost complete lack in conditional gp130Δhepa and c-Met/gp130Δhepa animals, 
whereas the c-MetloxP/loxP mice displayed a clear and strong activation of the 
STAT3 pathway (Fig. 29).  
 
 
Figure 29: Activation of the acute phase response c-Met/gp130loxP/loxP, c-MetΔhepa, gp130Δhepa 
and c-Met/gp130Δhepa mice were analysed for the activation of acute phase response mediators 
(pJNK, pSTAT3, pSTAT1). Western blot analysis for GAPDH was performed as a loading 
control. 
JNK1/2, an important stress activated protein kinase, whose activation is 
related to the APR was also significantly less phosphorylated in c-MetΔhepa, 
gp130Δhepa and c-Met/gp130Δhepa mice compared to c-Met/gp130loxP/loxP mice 
(Figure 20). Interestingly, the Interferon type 1 response factor STAT1 was not 
activated differentially in all mice without a detectable difference among the 
groups. 
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Next, STAT3 regulated gene expression was analysed. Serum Amyloid A 
(SAA), one of the main APR target proteins, whose expression is regulated by 
IL-6/gp130 (77).  mRNA expression was analysed by quantitavite Real-Time 
PCR (Fig. 21A). This showed a significant reduction of SAA mRNA expression 
3d post BDL in c-MetΔhepa-mice and an almost completely abolished induction in 
gp130Δhepa and c-Met/gp130Δhepa mice. A similar pattern was found for the 
mRNA of the STAT3 counter regulator SOCS3 (Fig. 30 B). Subsequent protein 
analysis by western blot showed a reduced signal in c-MetΔhepa mice and 
gp130Δhepa mice, whereas c-Met/gp130loxP/loxP mice displayed a slight increase 
of SOCS3 protein (Fig. 30 D). 
 
 
Figure 30: Molecular dissection of the Acute Phase Response after BDL Molecular 
dissection of the Acute Phase Response after BDL SAA (A), SOCS3 (B) and SOCS1 (C) 
were analysed on their mRNA-expression level. mRNA expression was validated against 
GAPDH as a housekeeping gene. *=p<0,05; **=p<0,01; ***=p<0,001; #=p<0,0001. D) Protein 
analysis of the STAT3 counter regulator SOCS3 was performed by Western blot with the 
determination of α-tubulin as a loading control.  
 
Suppressor of Cytokine Signalling 1 (SOCS1) mRNA was not regulated 
in either c-MetΔhepa nor gp130Δhepa or c-Met/gp130Δhepa mice, despite a strong 
induction in c-MetloxP/loxP-control mice 3 days after BDL (Fig. 30 C).  
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3.2.6 Proinflammatory cytokine expression during APR 
The expression of cytokines is important for the recruitment and homing 
of immune cells to the region of inflammation. Pro- and anti-inflammatory 
cytokines were analysed by quantitative Real-Time-PCR from mRNA from total 
liver extracts. The aim was to analyse their role in the inflammatory response 
after BDL depending on the used genotype. Messenger RNA expression 
analysis revealed that the proinflammatory cytokines IL-6, TNF-α, Oncostatin-M 
and IL-11 (Fig. 31 A, B, C and D) were upregulated in both c-Met and gp130 
deficient mice compared to c-MetloxP/loxP mice. While IL-1α was only upregulated 
in c-MetΔhepa and c-Met/gp130 Δhepa mice, IL-1β mRNA showed a significant 
induction pattern in again both c-MetΔhepa and gp130Δhepa mice (Fig. 31 E and F). 
The neutrophil recruiting factor KC was most significantly (27-fold) induced in c-
MetΔhepa, while the other groups showed only a modest induction post BDL (Fig. 
31G).  
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Figure 31: Expression analysis of proinflammatory cytokines after BDL mRNA expression 
of IL-6 (A), TNF-α (B), Oncostatin M (C), IL-11 (D), IL-1α (E), IL-1β (F), KC (G) was analysed by 
quantitative Realtime-PCR at day 3. All values are validated with GAPDH as a housekeeping 
gene. *=p<0,05; **=p<0,01 
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Figure 32: Anti-inflammatory response after BDL mRNA levels of HGF (A) and IL-4 (B) were 
analysed by Real-Time PCR at day 3 and 7 after BDL. Fold induction was validated against 
GAPDH as a housekeeping gene *=p<0,05; **=p<0,01  
 
On the opposite, the anti-inflammatory molecules HGF, IL-4 and IL-10 
were analysed. The analysis of their expression is important, as they define the 
resolution of the inflammatory response and the termination of the APR. HGF 
functions as an APR modulator and was expressed higher in all conditional 
knockout mice compared to control mice at day 3 post BDL with a significant 
induction in c-Met/gp130Δhepa mice. One of the main anti-inflammatory 
mediators is IL-4, whose expression was solely upregulated in c-MetloxP/loxP mice 
after bile duct ligation (Fig. 32B).  
 
3.2.7 Hepatic infiltration of immune cells after BDL 
The analysis of intrahepatic immune cells identified monocytes as the 
main form of infiltrating cells. An important subgroup of the monocytes are 
neutrophil granulocytes, also known as neutrophils. Immunofluorescent 
stainings revealed higher numbers of monocytes (CD11b) and neutrophils 
(Ly6G) in all conditional knockout mice compared to the control mice after BDL. 
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Figure 33: Identification of infiltrating immune cells Immunofluorescent stainings for CD11b+ 
cells were used to identify monocytes. CD11b+-cells are shown in (A) and the statistical analysis 
is illustrated in (B).   
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Figure 34: Analysis of infiltrating neutrophils Immune cells stained with Ly6G 3 days after 
BDL are shown in (A). Statistical analysis was undertaken by counting the total amount of 
positive cells per viewfield. This is displayed in panel (B). At least, 3 mice were analyzed and at 
least 7 high power view fields were counted.*=p<0,05; **=p<0,01; ***=p<0,005 #=p<0,0001 
 
Interestingly, c-Met, gp130 and c-Met/gp130 deficient mice displayed 
equal numbers of CD11b positive monocytes 3 days after BDL (Fig.34 A, B), 
whereas c-MetΔhepa and c-Met/gp130Δhepa mice showed the highest number of 
infiltrating neutrophils at day 3 post BDL (Fig. 35 A,B). Gp130Δhepa mice seemed 
to have a lower cell count for both immune cell species. 
The liver itself has resident macrophages, also known as Kupffer-cells. 
Their number and activation can also be used to analyse the degree of liver 
injury. 
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Figure 35: Staining of Kupffer-cells after BDL To detect Kupffer-cells, they were labelled by 
immunofluorescence with the marker F4/80. The staining is shown in (A) and the statistical 
evaluation is presented in (B).  
 
Immunofluorescence stainings for F4/80 positive cells revealed, as 
expected, present macrophages already at day 0 in the liver of all mice. At day 
3 their numbers increased in c-MetΔhepa and c-Met/gp130Δhepa more strongly 
than in gp130Δhepa or c-Met/gp130loxP/loxP mice (Fig. 35). 
 
3.2.8 Expression of antimicrobial peptides  
To defend the organism against bacterial or other microbial germs, 
immune cells, in this case especially neutrophils, express antimicrobial peptides. 
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Figure 36: Defensin expression after BDL Quantitative Real-Time PCR analysis was 
performed for the detection of defensin expression at day 3 post BDL. The mRNA-expression is 
shown as fold induction vs. GAPDH. *=p<0,05 
 
Real-Time PCR expression analysis of the defensin Cramp/LL37 mRNA 
displayed overall a strong induction after BDL. The most significantly induced 
expression was monitored in c-Met/gp130Δhepa mice compared to other used 
conditional knockout and control mice (Fig. 36).  
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4. Discussion 
Recorvery from liver injury is a complex process involving the activation 
of cytokines and growth factors. We have presented here a study dissecting the 
role of the HGF/c-Met system and its interplay with the IL-6/gp130 system in 
detail. 
HGF and its receptor c-Met have been shown to be indispensable for 
embryonic development and have furthermore been demonstrated to be 
involved in liver development (21). Interestingly, the first approach to delete c-
Met during embryonic development was not successful as these animals died in 
utero (Fig.10A). Therefore, these results suggest a further role for c-Met during 
liver development, most likely for embryonic hepatocytes – as only these cells 
express the albumin/AFP promoter/enhancer-dependent Alfp-Cre construct 
(182). These results are of specific interest as other genes such as members of 
the IKK complex, e.g. IKK2 or NEMO (183) and also gp130 (69), have been 
regarded as essential for liver development. However, their embryonic deletion 
only in hepatocytes (by using the Alfp-Cre construct) had no impact on liver 
development and animals were born normally (Fig. 10A) (77, 184). 
Hepatocyte growth factor (HGF) has been cloned and analyzed because 
of its essential role during liver regeneration and its well known involvement in 
liver remodelling and regeneration following hepatic injury. In earlier studies the 
role of HGF has been investigated by either overexpressing HGF or by deleting 
its receptor c-Met from the entire liver (44, 45, 185). 
 The role of IL-6/gp130 in the liver and its response to injury and infection 
has been studied extensively for more than a decade. It has been clearly 
illustrated that the lack of gp130 results in an enhanced liver damage (75, 77). 
In contrast to this, the impact of c-Met and its contribution to liver protection (36, 
44) along with the essential contribution of c-Met to the progress of liver 
regeneration (45, 185) has been recently discovered.  
 The analysis of early liver damage in the BDL model in wildtype, c-Met, 
gp130 and c-Met/gp130 deficient mice revealed that both receptors have a 
strong independent and combined impact in the prevention of early liver 
damage. An interesting effect was observed during the early phase of liver 
injury. Here gp130Δhepa and c-Met/gp130Δhepa mice displayed a higher mortality 
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than c-MetΔhepa and c-Met/gp130loxP/loxP when subjected to BDL (Fig. 20). 
Histological analysis revealed that c-Met/gp130loxP/loxP mice displayed only a 
mild liver damage in the histology 3 days post BDL, whereas all gene deficient 
mice showed numerous necrotic lesions (bile infarcts) compared to c-MetloxP/loxP 
mice. Interestingly, no significant differences were detected in serum measuring 
for bilirubin and transaminsase analysis (Fig.11B & 21 A,B).  
 The analysis of apoptosis revealed that c-MetΔhepa, gp130Δhepa and c-
Metgp130Δhepa had more apoptosis in the first 3 days post BDL (Fig. 14 & Fig. 
24, 25) in comparison to their littermate controls. It is remarkable that c-
Met/gp130Δhepa mice displayed a cumulative effect of the receptor deletions on 
apoptosis. This could be due to several reasons. It was demonstrated that c-
Met deficiency directly causes hypersensitivity towards FAS-induced apoptosis 
(Fig. 16 B, C) (29, 43, 186, 187). In the case of low or no presence of Fas-
ligand, c-Met inhibits the activation of FAS-induced pathways by binding to 
membrane bound the FAS-receptor (29, 43, 186, 187). In the case of the 
disassociation of the c-Met-FAS-R complex, e.g. induced by HGF or fatty acids 
(43), c-Met activates anti-apoptotic signalling pathways via the PI3K-AKT-Bad 
axis (29). It was demonstrated by Zhou et al. that a TyrLeuGlyAla (YGLA) 
sequence motif on the c-Met α-chain competes with FAS-L for the binding to the 
FAS-receptor (43). 
This study links those mechanisms to dysregulated expression of several 
anti-apoptotic genes, like TNFAIP3 (A20), GADD45α, β, γ .as found in our gene 
array analysis (Fig.15 & Table 3). TNFAIP2 has been described as a cytokine 
and a growth factor induced primary response gene (188) involved the 
development of hematopoetic tissue (188). The data presented here suggest a 
c-Met dependent antiapoptotic role of TNFAIP2 in hepatocytes during the BDL. 
These findings were consistent with data from Gomez-Quirroz et al., who 
described a disturbed redox-homeostasis leading to a higher FAS sensitivity for 
c-Met deficient primary hepatocytes (186). 
Gp130 deficient mice have been described to have absent acute phase 
response (74, 75, 77, 87). Furthermore, mice lacking the APR-induction 
displayed a higher mortality. This has been demonstrated in several mouse 
models. After BDL, mice with a ubiquitous conditional deletion of gp130 mice 
maintain a higher bacterial load in their livers (163). These prior findings were 
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the first hints that septicaemia could be a reason for the early death of these 
mice.  
The analysis of the acute phase response in our model revealed that the 
c-MetΔhepa mice had a reduced APR, due to a lower STAT3 phosphorylation 
status which led a lower mRNA expression level of SAA, one of the major acute 
phase proteins (153). STAT3 phosphorylation and expression of SAA were 
lacking in both gp130 and c-Met/gp130Δhepa mice (Fig. 29). Further analysis of 
the STAT1 activation revealed no differences in this pathway, whereas the 
activation of JNK was greatly reduced in c-MetΔhepa, gp130Δhepa and c-
Met/gp130Δhepa mice as compared to c-MetloxP/loxP mice (Fig. 29). STAT1 
mediated signalling results in activation of interferon type 1 and type 2 mRNA 
expressions (189). The absence of JNK activation in c-MetΔhepa and c-
Met/gp130Δhepa mice is most likely the result of the missing activation of the 
PI3K and the MAPK-kinase pathway in c-Met deficient mice (45). In the case of 
gp130Δhepa mice, impairment of TLR4 signalling might be one explanation for 
the missing JNK activation. Another possibility may be due to the impairment of 
the gp130 activated Ras-signalling pathway, which also results in JNK 
activation (89). Western blot analysis showed that STAT3-phosphorylation is 
reduced in c-MetΔhepa and was absent in the gp130 and the c-Met/gp130Δhepa 
mice after BDL (Fig. 19). SOCS3, the STAT3 suppressor molecule was found to 
be regulated differently as well. Western blot analysis demonstrated a 
degradation of SOCS3 in c-Met- and gp130Δhepa mice and no increase in the c-
Met/gp130Δhepa mice, whereas the c-Met/gp130lox/loxP mice showed an increased 
mRNA expression in Real-Time PCR analysis. This increase was also 
confirmed at the protein level via western blot analysis. Deficiency in activated 
STAT3 leads to a lack of acute phase protein expression such as serum 
amyloid A (Fig. 30A). The loss of SAA seems to be a critical point for the 
survival of septicaemia. Furthermore, the deficiency of IL-6 signalling 
counterregulation leads to an overshoot of the IL-6 signalling, which leads to a 
higher degree of liver inflamation. This also explains the high production of IL-6 
detectable in the c-MetΔhepa, gp130Δhepa and the c-Met/gp130Δhepa mice after 
BDL in comparision to c-MetloxP/loxP mice.  
One of the most striking findings in our study was the observation that c-
Met and c-Met/gp130Δhepa mice contained a higher number of bacteria, 
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detectable in liver and blood (Fig. 26 A, B). The analysis of the antibacterial 
defence, after BDL, showed a low expression of the LPS-binding protein (LBP) 
in the c-Met/gp130loxP/loxP mice and an increased expression in the c-MetΔhepa 
mice, whereas all gp130 knockout mice (gp130Δhepa and c-Met/gp130Δhepa mice) 
lacked expression of LBP (Fig. 27 A). While the LBP co-receptor CD14 was 
highly expressed in the c-MetloxP/loxP and the gp130Δhepa mice, the c-MetΔhepa and 
c-Met/gp130Δhepa mice had a significantly lower expression of this factor (Fig.27 
B). 
The different regulation of CD14 and LBP lead to the assumption that 
CD14 is regulated by HGF/c-Met. It was demonstrated for LBP to be regulated 
by IL-6/gp130 as well as IL-1 mediated signalling. Further data provided in this 
thesis also implies, besides the lack of gp130 mediated signalling, an impaired 
IL-1 receptor signalling due to a missing expression of MyD88. LBP and CD14 
are for the recognition of LPS and to induce antibacterial signalling via TLR4 
(181). Analysis of the TLR4 signalling pathway showed an increase of TLR4 
mRNA expression 3 days after BDL in c-MetΔhepa, gp130Δhepa and c-
Met/gp130Δhepa mice (Fig. 28A) as compared to littermate controls. Further 
investigation of TLR4 signalling by Real-Time PCR revealed a reduced mRNA 
expression of the TLR4 signaltransducer MyD88 in mice lacking gp130, 
whereas in c-MetΔhepa mice expression of MyD88 was increased (Fig. 28B). A 
downstream target of MyD88 is Irak4. This kinase is activated by 
phosphorylation governed by MyD88 (190). The expression analysis of this key 
molecule in TLR4 signalling displayed an induction of Irak4 mRNA expression in 
c-Met/gp130loxPloxP mice, whereas its expression was not induced in all other 
genotypes (Fig. 28D). Beside the defect in the gp130 signalling, this implies that 
the gp130Δhepa and the c-Met/gp130Δhepa mice additionally have impairment in 
the TLR4 signalling pathway. JNK  a downstream target of TLR4 signalling  is 
impaired in all used knockout mice as well. TLR4 signalling is activated by LPS 
(181). These signals are transmitted via MyD88 to Irak4, which recruits and 
activates Irak1 by phosphorylation. Later Irak1 dissociates from its complex with 
Irak4 and forms a complex with TAK1, TAB1 & 2, which finally leads to 
activation of c-Jun kinase (JNK) (191). Deficiency in MyD88 transduced 
signalling affects the IL-1 receptors (192). This also indicates that gp130Δhepa as 
well as c-Met/gp130Δhepa mice do not only lack gp130 or c-Met, respectively but 
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that they also have an impaired TLR4 and IL-1 signalling. C-MetΔhepa mice and 
the c-Met/gp130loxP/loxP mice seem to be competent to induce TLR and IL-1 
pathways in the liver.  
A further downstream signal mediator of TLR4 that was shown to be 
affected is Tirap (Fig. 28C). Tirap is mediating TLR4-signalling via either a 
MyD88 dependent or independent manner (193). It has been demonstrated that 
Tirap is associated with the clearance of LPS in the liver (194). Tirap finally 
activates p38-kinase, an important mediator of antibacterial signalling and LPS-
clearance, via the E3 ligase Traf6. Traf6 itself belongs to the Traf6-ASK1 
(Apoptosis signalling regulating kinase 1 /Map3k5)-p38 axis, which was 
described to be involved in the mammalian innate immune response (195). The 
mRNA expression of Tirap was significantly downregulated in c-MetΔhepa, 
gp130Δhepa and c-Met/gp130Δhepa mice as compared to c-Met/gp130loxP/loxP mice 
(Fig. 28C). This indicates very clearly that in all studied knockout mice the anti-
LPS signalling is at least impaired. Furthermore, LiTAF an LPS induced 
transcription factor was significantly downregulated in the gp130Δhepa and the c-
Met/gp130Δhepa mice (Fig. 27 C). The LPS induced CXC-cytokine (LIX) 
displayed bacterial load dependent expression in c-MetΔhepa and gp130Δhepa and 
the c-Met/gp130Δhepa mice. This indicates that either this not expressed in 
hepatocytes alone or the pathway is not affected in the knockout mice. 
Cytokines and growth factors are crucial for the induction of the APR as 
well as for the activation of hepatic stellate cells and the recruitment of immune 
cells during liver injury. We have shown enhanced expression levels for the 
major proinflammatory cytokines (IL-6, TNF-α, IL-1α & β) in c-MetΔhepa, 
gp130Δhepa and c-Met/gp130Δhepa in comparison to the c-Met/gp130loxP/loxP mice 
(Fig. 31A-G). However, the neutrophil recruiting factor KC was found to be 
increased in c-MetΔhepa mice, while gp130Δhepa mice showed only a weak 
induction of KC mRNA expression 3 days post BDL. Whereas CD11b+ cells 
were equally represented in the livers of c-MetΔhepa, gp130Δhepa and c-
Met/gp130Δhepa mice as compared to c-Met/gp130loxP/loxP (Fig. 33 A& B), Ly6G+ 
(Fig. 34A & B) )and F4/80+ (Fig. 35 A & B) cells were found less in the liver of 
gp130Δhepa mice. This indicates an imbalanced recruitment of immune cells due 
to a missing regulation of proinflammatory cytokine expression. 
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The analysis of the anti-inflammatory cytokines unravelled a high 
expression of IL-4 already at day 3 in the c-Met/gp130loxP/loxP mice, whereas c-
MetΔhepa mice displayed a significantly lower transcription of IL-4 mRNA and the 
expression is not induced at day 3 in the gp130Δhepa and the c-Met/gp130Δhepa 
mice (Fig. 32B). IL-4 has been described as one of the most important anti-
inflammatory cytokines. It is involved in the resolution of the acute phase 
response and its reduced expression indicates an impaired regulation of the 
acute phase response. Hepatocyte Growth Factor was described as an APR-
modulating molecule (153). It is higher expressed in c-MetΔhepa, gp130Δhepa and 
c-Met/gp130Δhepa mice compared to c-MetloxP/loxP mice. It might have an effect on 
cytokines such as TNF-α, Oncostatin-M, and IL1-α, which were significantly 
lower expressed in the gp130Δhepa mice compared to c-MetΔhepa and c-
Met/gp130Δhepa mice. Furthermore, HGF seems to contribute the expression of 
SAA, which was lower expressed in the absence of c-Met as compared to c-
MetloxP/loxP mice. The proinflammatory cytokine KC seems to be an additional 
downstream target regulated by c-Met. In absence of c-Met but presence of 
gp130 its mRNA expression is strongly overexpressed (Fig. 12D, E & 31G) as 
compared to c-Met/gp130loxP/loxP. 
The innate immune response is the opponent of bacteria induced sepsis. 
Immune cells are recruited to the origin of inflammation. In case of the liver, 
immune cells infiltrate from the blood into the liver. It has been described that 
among the analysed immune cells, neutrophils and macrophages play an 
important role in the innate immune response against bacterial sepsis. The 
antibacterial effect is mediated by the adsorption of bacteria and the lysis of the 
cell in the lysosomes. Another antibacterial agent is the secretion of 
antimicrobial peptides by immune cells. These peptides build a pore into the 
bacterial cell wall, thus inducing the death of bacteria. In this study the 
expression of the antimicrobial peptide (AMP) LL37/Cramp (cathelin-related 
antimicrobial peptide) was analysed as a neutrophil derived AMP (196-198). 
Real-Time PCR analysis unravelled an almost equal expression of its mRNA 
levels in c-Met/gp130loxP/loxP, c-MetΔhepa and gp130Δhepa mice (Fig. 36). 
LL37/Cramp is significantly higher expressed in the c-Met/gp130Δhepa mice. The 
expression of LL37/Cramp is regulated by various cytokines such as TNF-α, IL-
1β and IL-6 (personal communication with Dr. rer. nat. L.-O. Brandenburg). This 
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indicates that the neutrophils, that are recruited to the battle against the 
bacterial inflammation, and that the innate immune response is functionally 
active in mice carrying a hepatocyte specific knockout for gp130 and c-Met. 
This furthermore indicates that also the hepatocyte itself might have a more 
important role in antagonizing bacterial inflammation. Whether LL37/Cramp 
plays a role in liver injury remains unclear yet (personal communication with Dr. 
rer. nat. L.-O. Brandenburg). 
Due to the strong inflammatory response caused during the immediate 
phase after BDL, hepatic stellate cells become activated. Thus, in the long run, 
due to the constant cholestasis, a fibrogenic response is triggered. As the role 
of c-Met during chronic liver injury was still undefined, we aimed to analyse c-
MetΔhepa mice in this regard. We were able to assertain a stronger expression of 
α-SMA in stellate cells (myofibroblasts) in c-MetΔhepa mice as compared to c-
Met/gp130loxP/loxP mice (Fig 17C, D). This correlated with higher mRNA levels of 
the profibrotic cytokine TGF-β1 (Fig. 17A), which is known to be one of the main 
inducers of HSC activation, and a higher expression of TLR4, which also 
functions as a profibrotic factor (111) (Fig. 17B). The stronger activation of the 
HSCs can also be a reason for the enhanced KC expression observed in c-
MetΔhepa mice, because HSCs are one of the main producers of KC (199). Thus, 
mice with a hepatic deletion of c-Met are primed towards a stronger fibrotic 
phenotype already during the early phase after BDL.   
The development of liver fibrosis is related to the accumulation of 
extracellular matrix produced by myofibroblasts. The Sirius red staining 
displayed a stronger deposition of collagen in the liver parenchyma of c-MetΔhepa 
mice (Fig. 18A, B); this was be confirmed by mRNA expression analysis using 
Real-Time PCR for Collagen1α (Fig. 18C). Another important factor for the 
development of fibrosis is the differential expression of matrix-metalloproteases 
(MMPs). Here, we analysed MMP-13, a metalloproteinase that has been shown 
to be predominantly induced after BDL (126) by Real-Time PCR and confirmed 
its higher expression in c-MetΔhepa mice as compared to c-MetloxP/loxPmice (Fig. 
18D). This was associated with a 6 times higher expression of the 
counterregulator TIMP-1 (Fig. 18E) compared to MMP-13. Other important 
activators of hepatic stellate cells are platelet derived growth factors. PDGF-D, 
which is specific for the activation of stellate cells during BDL (178), was 
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significantly higher expressed in c-Met deficient compared to wildtype mice (Fig. 
18F).  
Moreover the development of the higher degree of liver fibrosis in c-
MetΔhepa mice after BDL was linked to the regenerative cellular response after 
liver injury. Proliferation analysis by using a BrDU assay revealed that c-
MetΔhepa mice do have a significant lower hepatocyte proliferation rate than c-
MetloxP/loxP mice (Fig. 14C, D). The lower rate of proliferating hepatocytes was 
shown to be related to the lack of p21 regulation and the inability to 
phosphorylate RB in the c-MetΔhepa mice (45) in the partial hepatectomy model. 
Together with the higher rate of apoptosis at day 3 and day 7 post BDL it is 
comprehensible that the lack of compensatory proliferation is due to the missing 
c-Met signalling pathway.  
 
Taken together we were able demonstrate, that c-Met and gp130 are 
essential to maintain liver homeostasis and to overcome acute as well as 
chronic liver injury in a model of chronic cholestatic liver injury. It was verified 
that lack of c-Met activation in hepatocytes result in stronger fibrosis 
progression.  
The role c-Met in particular was determined more precisely. Beside the 
protective mediation of antiapoptotic signalling and the proliferation of 
hepatocytes after BDL, c-Met does participate in the activation of the APR by its 
contribution to the activation of STAT3 and JNK resulting in the expression of 
SAA and SOCS3. Furthermore, c-Met signalling participates in the antibacterial 
signalling by regulating the LBP coreceptor CD14, which functions as a relay 
protein for the activation of the TLR4 signalling pathway.  
Gp130 is directly linked to the APR and the survival of the immediate 
phase of the BDL. The lack of STAT3 signalling is so essential that its absence 
results in a higher mortality after BDL already during the acute phase reaction. 
As a new player in the acute phase response of the liver the LPS-induced TNF-
α Factor (LiTAF) can be introduced. This is a LPS induced transcription factor, 
which is in the case of the liver at least coregulated by the gp130-STAT3 axis. 
Together with LiTAF also STAT6B enters the focus of APR-investigation 
because interaction of both was shown to initiate LiTAF mediated gene 
expression at least in macrophages (179). It seems likely that this mechanism is 
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also relevant for hepatocytes and plays a more crucial role in the liver than in 
macrophages. Furthermore, the Toll-like receptor signal transmitter MyD88, 
whose gene expression is regulated by IL-6/gp130 (200), is essential for the 
regulation of antibacterial signalling.  
Together, HGF/c-Met and IL-6/gp130 participate in the initiation and the 
resolution of the APR. They initiate the correct antibacterial signalling by 
regulating either CD14 or LBP and are involved in the regulation of the kinase 
Irak4 and the TLR-signalling transducers MyD88 and Tirap. 
Finally, HGF/c-Met and IL-6/gp130 do not only participate by their own 
pathways to Hepatocyte welfare, but they also contribute to components of the 
TLR4 signalling pathway, as it can be described for Tirap, MyD88 and Irak4. 
The lack of the c-Met pathway is not lethal, but results in a higher degree of liver 
injury, the impact of the IL-6/gp130 pathway on the APR and antibacterial 
signalling together with induction of the innate immune response mediated by 
TLR4 signalling transducers MyD88 and Tirap, leads to a higher mortality in 
gp130Δhepa and c-Met/gp130Δhepa mice during the early phase of the BDL-model. 
A side effect on the MyD88 deficiency is the inhibition of the IL-1 receptor 
pathway, whose signalling is also mediated by MyD88. The impaired activation 
of these pathways results in death by bacterial sepsis and in the case of the c-
MetΔhepa mice in a higher degree of liver injury, finally leading to a stronger liver 
fibrosis progression. 
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 Abbreviations 
Abbreviation Full term 
AA aminoacid 
ADAM 10 & 17 A Disintegrin And Metallopeptidase 10 & 17 
ALT Alanine transaminase 
APP Acute phase protein 
APS Ammonium persulfate  
a-SMA alpha-smooth muscle actin 
AST Aspartate transaminase 
ATP Adenosine triphosphate 
bp basepairs 
BDL Bile duct ligation 
BrDU Bromodeoxyuridine 
BSA Bovine serum albumine 
CRP C-reactive protein 
C/EBP-β CCAAT-enhancer-binding proteins 
cDNA complementary Desoyribonucleic acid 
CTGF connective tissue growth factor 
CTNF Ciliary neurotrophic factor 
DAPI 4',6-diamidino-2-phenylindole 
dH2O destillated H2O 
Δhepa hepatocyte specific knockout  
dNTPs deoxyribonucleotides 
EGF Epidermal growth factor, 
FASL Fas-ligand 
FASR Fas-receptor 
FGF Fibroblast growth factor 
Fig. Figure 
fwd forward 
Gab1 GRB2-associated-binding protein 1 
GAPDH Glyceraldehyde 3-phosphate dehydrogenas 
gp130 Glycoprotein 130 
Grb2 Growth factor receptor-bound protein 2 
h hour 
H&E Haematoxylin & Eosin 
HGF hepatocye growth factor 
HRP horseradish peroxidase 
IGF Insulin-like growth factor 
IgG Immunoglobulin G 
IL-11 Interleukin-11 
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 IL-31 Interleukin-31 
IL-4 Interleukin-4 
IL-6 Interleukin-6 
IL-6R Interleukin-6 receptor also known as gp80 
Irak4 interleukin-1 receptor-associated kinase 4) 
JAK Janus kinase 
KC C-X-C motif ligand 1 
Kda KiloDalton 
LIF Leukaemia inhibitory factor 
LiTAF LPS induced Tumor necrosis factor alpha homolog 
LIX LPS induced CXC-chemokine 
LPS Lipopolysaccharide 
mA milliampere 
Met mesenchymal-epithelial transition factor 
MMP13 Matrix Metalloprotease also known as collagenase 3 
MyD88 Myeloid differentiation primary response gene  
NFkB nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF Nerve growth factor 
OSM Oncostatin M 
PBS Phosphobuffered saline 
PCR polymerase chain reaction 
PDGF Platelet derived growth factor 
R Single letter code for argenine 
rev reverse 
RIPA Radio immunoprecipitation buffer 
RT room temperature 
RTK receptor tyrosine kinase 
SAA  Serum Amyloid A 
SDS-PAGE Sodiumdodecylsulfate polyacrylamide gelelectrophoresis 
SOCS1& 3 supressor of cytokine signalling 1/3 
STAT1 & 3 Signalling transducer and activator of transcription 1 & 3 
  
TBS Tris buffered saline 
TBS-T Tris buffered saline supplemented with Tween 20 
TGF-b1 transforming growth factor beta1 
Tirap Toll-interleukin 1 receptor domain containing adaptor protein 
TIMP-1 tissue inhibitor of metalloproteinases 
TLR4 Toll-like receptor 4 
TNF-a Tumor necrosis factor alpha 
TNFAIP2 Tumor necrosis factor alpha induced protein 2 
TNFAIP3 Tumor necrosis factor alpha induced protein 3 
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 TPR-MET translocated promoter region fused to met 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling  
V Single letter code for valine 
wt wildtype 
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 Zusammenfassung 
 
Hepatocyte growth factor (HGF), sein Rezeptor c-Met und Interleukin-6 
(IL-6), gemeinsam mit seinem Signaltransduktor gp130, sind wichtige 
Mediatoren der Leberregeneration und leberprotektiver Effekte. C-Met und HGF 
sind für die Leberentwicklung während der Embryogenese als auch, für die 
Leberregeneration, nach einer Schädigung essentiell. IL-6/gp130 vermittelte 
Signalwege sind wichtig für die Regulation der Akut-Phase-Antwort im Rahmen 
einer akuten Leberschädigung, ebenso wie die Modulation der 
Leberregeneration und der Immunzellhomöostase. 
Ziel dieser Arbeit ist die Untersuchung der Effekte der von HGF/c-Met 
und IL-6/gp130 vermittelten Signalwege im Gallengangsligaturmodell (BDL), 
welches eine chronisch-cholestatische Leberschädigung induziert und in deren 
Verlauf ein fibrotischer Prozess in Gang gesetzt wird. In dieser Thesis wurden 
Wildtyp-Mäuse (c-Met/gp130loxP/loxP), konditionale c-Met knockout Mäuse, 
konditionale gp130 defiziente Mäuse (gp130Δhepa) und konditionale c-Met/gp130 
Doppelknockout Mäuse 4 Wochen lang der Gallengangsligatur unterzogen.  
Die konditionalen Knockout-Tiere wurden mit dem Cre-LoxP-System 
generiert. Ein erster Versuch der hepatozytenspezifischen Deletion von c-Met 
mittels eines prä-natalen Albuminpromoters führte zu embryonaler Lethalität. 
Der Wechsel hinzu einem postnatal aktivierten, hepatozytenspezifischen 
Albuminpromoters ermöglichte lebende Nachkommen mit c-Met defizienten 
Hepatozyten. 
In vorhergehenden Experimenten konnte ein Zusammenhang zwischen 
einer erhöhten Leberschädigung und fehlender c-Met-vermittelter 
Signaltransduktion hergestellt werden. Hierbei konnte gezeigt werden, dass c-
Met-Defizienz mit erhöhter Sensitivät für pro-apoptotische Signalwege des FAS-
Todesrezeptors assoziiert ist, da c-Met die Expression wichtiger anti-
apoptotischer Gene reguliert. Resultat dieser Sensitivität ist eine erhöhte 
Schädigung der Leber.  
Im Zusammenhang mit der verstärkten Leberschädigung steht außerdem 
eine Entzündung der Leber in c-MetΔhepa-Tieren im Vergleich mit c-
Met/gp130loxP/loxp-Tieren. Die Kombination aus fehlender anti-apoptotischer 
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 Genexpression und erhöhter Entzündungsreaktion resultiert in einem höheren 
Grad der Leberfibrose.  
Ein weiterer Teil dieser Arbeit befasst sich mit dem Einfluss von HGF/c-
Met und Il-6/gp130 auf die Regulation der Akut-Phase-Antwort. Während der 
ersten 7 Tage nach BDL zeigten gp130Δhepa und c-Met/gp130Δhepa-Mäuse eine 
erhöhte Mortalität im Vergleich zu c-MetΔhepa und c-Met/gp130loxP/loxP Tieren. Als 
Grund für die erhöhte Sterblichkeit konnte eine bakteriell induzierte Sepsis 
identifiziert werden und eine vergleichende Signalwegsanalyse ergab eine 
fehlende Akut-Phase-Antwort und fehlerhafte antibakterielle 
Signalwegstransduktion in gp130Δhepa und c-Met/gp130Δhepa Tieren. Im 
Gegensatz dazu hatten c-MetΔhepa Mäuse eine reduzierte, aber immer noch 
funktionierende Akut-Phase-Antwort. 
Sowohl c-Met als auch gp130 tragen zur Leberprotektion bei und spielen 
eine wichtige Rolle für die Regulation, als auch die Modulation der Akut-Phase-
Antwort. Sie partizipieren in spezifischen Signalwegen, wie der Anti-
apoptotischen Genexpression, so im Fall von c-Met und den antibakteriellen 
Signalwegen im Fall von gp130, in Signalwegs, wie auch Liganden spezifischer 
Art und Weise. 
 Die hier beschriebenen Ergebnisse ermöglichen ein tieferes Verständnis 
der signalwegsspezifischen Effekte, welche durch c-Met und gp130 im Rahmen 
der chronischen Cholestatischen Lebererkrankung vermittelt werden. Dies 
unterstützt die Anstrengungen der Suche nach einer Behandlung der 
Leberfibrose und ermöglicht die bessere Behandlung von bakteriellen Sepsen. 
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